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Abstract. 
MODULATION OF GENE EXPRESSION BY TUMOR-DERIVED MUTANT p53. 
ROLE OF TRANSACTIVATION IN GAIN-OF-FUNCTION. 
By 
Mariano J. Scian, Bachelor of Science, EMT-I 
Virginia Commonwealth University, Richmond, Virginia. 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University. 
Virginia Commonwealth University, 2005. 
Director: Sumitra Deb, Ph.D. 
Professor, Department of Biochemistry 
It was hypothesized that the C-terminal sequences for mutant p53 would be required 
for oligomerization, and oligomerization may be critical for gain-of-function. An N­
terminal deletion mutant of p53 that deletes amino acids 1 -293 was used as a tool to 
perform hetero-oligomerization studies. This mutant retains the entire oligomerization 
domain but dispenses off the transactivation domain and a large portion of the sequence­
specific DNA-binding domain. Co-transfection experiments show that p53 del. 1 -293 
forms hetero-oligomeric complexes with p53-D281 G. Also, co-expression of p53 del. 1 -
293 with p53-D28 1 G inhibited p53-D281 G-mediated transactivation of the EGFR and 
MDRI promoters suggesting that hetero-oligomerization inactivates transcriptional 
functions of mutant p53. The interaction of p53 del. 1 -293 and p53-D281 G reduced 
transactivation potential of p53-D281 G in stably transfected 1 0(3) murine cells. 
Therefore, the data presented supports the idea that proper oligomeric forms of mutant 
p53 are required for its transactivation function. Expression of mutant p53-D281 G also 
resulted in increased growth rate (H 1 299 cells), decreased chemosensitivity (H1299 and 
2 1 PT cells) and increased plating efficiency (Saos-2 cells). Expression of a 
transactivation deficient mutant p53 did not induce gain-of-function properties (increased 
growth rate and decreased chemosensitivity). Unlike the other gain-of-function 
properties tested, soft agar plating efficiency in Saos-2 cells was not significantly affected 
by the expression of a transactivation deficient mutant p53, suggesting that 
transactivation may not be the only factor affecting this gain-of-function property. In 
order to identify the genes responsible for the observed phenotypes, global gene 
expression analyses were carried out using p53-null H 1 299 cell stably transfected to 
express mutant p53 (-R1 75H, -R273H and -D28 1 G). A thorough and stringent analysis 
revealed 1 50 genes up-regulated by the expression of mutant p53. Up-regulation of a 
number of these genes was confirmed by QPCR and transient transcriptional promoter 
analyses; expression of the transactivation deficient mutant p53-D281 G  (L22Q/W23S) 
did not result in up-regulation of the tested genes further supporting the idea that 
transactivation of genes is directly related to gain-of-function phenotypes. Using the 
ASNS gene as a model, this transactivation by mutant p53 was concentration dependent 
and that the increased transcription did indeed result in increased protein levels. 
2 
H. Chapter 1. Introduction 
Structure and function of p53. The tumor suppressor p53 gene is located on 
chromosome 1 7p and encodes an oligomeric, nuclear phosphoprotein that acts as a tumor 
suppressor. It is a sequence-specific DNA-binding protein and transcriptional activator 
as well as a transcriptional repressor [ 1 -9]. The consensus DNA-binding site contains 
two copies of the 1 0  bp motif 5'-PuPuPuCWWGPyPyPy-3', separated by 0 to 1 3  bp [ 1 0]. 
(Pu denotes purine base, Py denotes pyrimidine base and W denotes A or T). All p53 
genes from evolutionarily distant species contain five highly conserved regions 
designated domains I-V [ 1 1 ,  12] (Figure 1). 
The sequence-specific DNA-binding domain of p53 is found in the central region 
covering the conserved domains II-V (residues 100-293) [13- 1 9]. Additionally, p53 
contains a transactivation domain located within residues 1 -73 [20-27], and an 
oligomerization domain located within residues 320-360 [ 1 6, 1 9, 23, 28-30]. Sequences 
found within the central DNA binding domain are highly evolutionary conserved [ 1 9]. 
Figure 1 .  Structure of WTp53. 
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The tumor suppressor p53 has a very short half-life. Levels of p53 in a cell rise after 
stress like DNA damage, heat shock, hypoxia or hyperoxia among other stress signals. 
Elevated levels of wild-type p53 (WTp53) in response to cellular stress situations lead to 
apoptosis or cell cycle arrest [2, 3 1 -4 1 ]. Initial studies on the cell cycle with ionizing 
radiation (IR)-exposed cells found that cells expressing a mutated p53 protein failed to 
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arrest the cell cycle at the G1/S checkpoint [42]. Subsequently, it was found that 
p2 1 1W AF - I ,  an integral component of this checkpoint, was under the transcriptional 
control of p53 [40]. Exposure of cells to IR led to an increase in WTp53 protein levels, 
which in turn resulted in elevated levels of p2 1 IW AF-I arresting the cells at the G(/S 
checkpoint. Evidence exists that p53 is involved in a G2/M checkpoint and that loss of 
this checkpoint contributes to an increase in polyploid cells [43]. 
The role of p53 in apoptosis involves the transcriptional up-regulation of Bax, a pro­
apoptotic protein [44]. It has also been shown that p53 can down-regulate expression of 
the anti-apoptotic protein bcl-2 by interacting with the TAT A binding protein to repress 
transcription of the gene [44-46]. More recently, a role for p53 has been described at 
the mitochondrial level, where p53 is sensitive to the levels of bcl-2 and Bax [47, 48]. 
More evidence is accumulating describing a role for p53 in DNA excision repair, both as 
a transcription factor, up-regulating the synthesis of the repair enzyme 06-alkylguanine 
transferase and the p48 subunit of the DNA damage binding protein (DDB2) and as a 
component of the nucleotide excision repair (NER) complex by interacting with XPB and 
XPD components of the NER-associated TFIIH transcription/repair complex [49-5 1 ]. 
The p53 protein can also interact with RAD51, topoisomerase-I and topoisomerase-II, 
each of which plays a role in recombination, DNA repair and DNA replication [52-55]. 
All in all, it is evident that p53 is involved in many crucial processes within the cell 
(Figure 2). 
I;legradation and regulation of p53. As mentioned, elevated levels of WTp53 in 
response to cellular stress situations leads to apoptosis or cell cycle arrest [2, 3 1 -4 1 ]. 
Accumulation of p53 occurs through an increased translation rate and decreased 
degradation rate [56, 57]. Under normal circumstances, the levels of p53 are regulated 
through its interaction with the mouse double minute 2 protein (MDM2) [58, 59]. 
MDM2 binds to p53 and maintains relatively low levels of p53 in the cell by 
increasing its susceptibility to proteolysis by 26S proteosome and acting as a ubiquitin 
ligase [58, 59]. Under stress the MDM2-p53 interaction is blocked and the levels of p53 
in the cell rise. It has also been reported that p53-MDM2 complex must be shuttled from 
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the nucleus to cytoplasm for p53 to be degraded. [60-63]. Also, during stress human pl4 
ARF is induced and it stabilizes p53 as it inhibits degradation of p53 by MDM2 [64, 65]. 
Additionally, aside from targeting p53 for degradation, MDM2 can also inhibit p53's 
transcriptional activity by physically interacting with the N-terminus of p53 [64,65]. 
Figure 2. Functions of WTp53. 
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The p53 protein also undergoes numerous post-translational modifications during its 
activation. Specific phosphorylation sites have been identified within its amino and 
carboxy termini [9, 34, 36, 66-76]. The amino terminal domain undergoes 
phosphorylation by various kinases that include, casein kinase, checkpoint kinase 1 and 
checkpoint kinase 2, DNA-dependent protein kinase ataxia telangiectasia mutant, jun 
kinase and mitogen activated kinase (MAPK) [67, 70, 74]. The carboxy terminus can be 
phosphorylated by various cyclin dependent kinases (CDKs) and protein kinase C (PKC). 
Additionally, various acetylation sites have been also identified [67, 70, 74]. 
Phosphorylation of the N-terminus results in a conformational change that enables 
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transcriptional activation of genes, has some effects on DNA binding and results in a 
decreased interaction with MDM2 [77]. Changes in the phosphorylation state of the 
carboxy terminus have also been shown to affect the conformation of the protein and to 
modulate DNA binding activity [78]. 
Cancer with mutant p53 is more aggressive than cancer without p53. Over 80% 
of p53 mutations found in human tumors are missense mutations and in most human 
cancers only the mutant protein is expressed [6, 20-22, 79-84]. The percentage of 
missense mutations found in the p53 gene is significantly larger than that found for other 
tumor suppressor genes [85, 86]. The high frequency of mutation combined with the 
apparent selective over-expression of the mutant protein suggests that mutations in the 
p53 gene not only destroy the tumor suppressor function of the WT protein, but also that 
the mutant protein may gain oncogenic functions. This hypothesis predicts that tumors 
expressing mutant p53 may be more aggressive than p53-null tumors and suggests that 
patients with tumors expressing a mutant p53 have a poorer prognosis than patients with 
tumors lacking p53 altogether. This is true for a number of human cancers [87- 1 06]. For 
example, cervical cancers with human papilloma virus (HPV) (which are functionally 
p53-null) have a better prognosis than those with mutant p53 (and without HPV) [ 1 1, 
1 07- 1 14]. 
Types of p53 mutations. While most tumor suppressor genes are inactivated by 
mutations leading to an absence of protein synthesis, more than 80% of alterations in the 
p53 gene are missense mutations that lead to the synthesis of a stable full-length protein 
[18]. In fact more than 50% of human cancers contain a p53 mutation [6, 20-22, 79-84]. 
Broadly, three types of p53 mutations can be identified [ 1 ,  5): 1) loss-of-function, 
where the tumor suppressor activities of p53 are abolished; 2) dominant-negative, where 
hetero-oligomeric complex formation between wild-type and mutant p53 drives the wild­
type p53 into a mutant conformation and results in the inactivation of wild-type p53 
present in the cells; and 3) gain-of-function, where mutant p53 attains a dominant 
oncogenic role that does not depend on complex formation with wild-type p53. 
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These three categories are based on the following observations: I )  many cancers have 
lost wild-type p53 functions [20, 2 1 ]  and p53-1- mice are highly prone to tumor 
formation, confirming that loss-of-function can result in tumorigenesis; 2) Patients who 
inherit the Li-Fraumeni cancer syndrome (LFS) and p53+1- mice develop tumors early 
[ 1 1 5]; 3) Many tumors with mutations in the p53 gene retain and over-express the mutant 
allele protein implying that mutant proteins perform a vital oncogenic role, and hence are 
selectively over-expressed [6, 20-22]. The selective over-expression of mutant p53 is 
believed to be required for both dominant-negative and gain-of-function activities [ 1 1 ,  
1 8, 1 1 6, 1 1 7]. 
Walker el al [ 1 1 8] used the IARC database to define 73 "hotspots" for mutations in 
the p53 gene. Interestingly, most of these "hotspots" were found at CpG dinucleotides 
within exons 5-8 of p53. Six of these CpG "hotspots" were identified within the DNA 
binding domain of p53 at residues 1 75, 2 1 3, 245, 248, 273, and 282 [ 1 9]. These residues 
are either directly involved in protein-DNA contact (Class I mutants, i.e. R248W and 
R273H) or are critically important for maintaining protein structure (Class II mutants, i.e. 
RI 75H) [ 1 1 9]. 
Most naturally arising p53 mutations exhibit an increased stability and accumulate to 
high levels yet are unable to function normally and fail to induce the proper response 
after cellular stress [ 1 1 9]. Cho el al [ 1 7] showed through X-ray crystallography that in 
general mutations of p53 alter the ability of the protein to bind to the promoter regions of 
genes under its regulatory control. This presents a convincing explanation for loss-of­
function and dominant-negative mutations, which are unable to induce genes such as 
p2 1 1W AF -I and Eax that would normally result in cell cycle arrest or apoptosis. 
However, it does not explain how mutant p53 can act as a gain-of-function mutation. 
Tumor-derived p53 mutants and gain-of-function. As mentioned earlier, WTp53 
is a sequence-specific transactivator of genes containing p53-binding sites on their 
promoter or transcriptional regulatory sequences [I I ]. Elevated levels of WTp53 in 
response to cellular stress situations lead to apoptosis or cell cycle arrest at the Gt or G2 
boundaries by inducing expression of genes that are involved in various aspects of 
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cellular growth regulation [2, 3 1 -41). Tumor-derived p53 mutants are defective in these 
functions (Ioss-of-function). 
The high frequency of missense mutation (as opposed to deletions or truncations) 
distinguishes p53 from other tumor suppressors and suggests that there is a selective 
pressure for mutant p53. Indeed, expression of mutant p53 in cells devoid of endogenous 
WTp53 has been shown to induce various growth promoting and proliferative functions 
[11 ,  120- 1 30). These activities are not shared with wild-type p53. 
One of the most important discoveries with regard to mutant p53 gain-of-function 
was the ability of the mutant protein to enhance the tumorigenicity of cells lacking 
expression of p53 [ 1 1 ,  129-1 32]. Through the years, various activities have been 
attributed to mutant p53, which include (I ) increased tumorigenicity [ 1 33, 1 34], (2) 
increased metastasis and tissue invasiveness [ 1 35], (3) increased growth in soft agar 
[136], (4) decreased sensitivity against chemotherapeutic drugs [ 1 37, 1 38], (5) increased 
resistance to y-irradiation [ 1 39], (6) accelerated chemical carcinogenesis [ 1 40], (7) 
increased homologous recombination induced by ionizing radiation [ 1 40], (8) disruption 
of spindle check point [ 1 24], (9) activated topoisomerase I activity [ 1 41], (10) increased 
growth rate [ 1 42] and (1 1 )  induction of gene amplification [ 1 43). Many of the gain-of­
function data come from p53-null systems (eliminating the possibility of dominant­
negative effects) where the expressed mutant p53 level was comparable to that observed 
in cancer cells [ 1 29). This suggests the strong possibility that mutant p53 gain-of­
function has a true physiological role, which may lead to aggressive cancer development 
and poorer prognosis. 
Most of the gain-of-function properties have been demonstrated using p53-null cell 
culture systems. This is not an ideal system, since cells may accumulate further 
mutations while in culture, making the system an inaccurate representation of human 
tumors. To this end, mouse models have been generated in order to further understand 
the role of mutant p53 in oncogenesis. It has been observed that p53-null mice develop 
early onset lymphomas making long term studies of gain-of-function in these mice a bit 
complicated [ 1 44). Using a knock-in mouse line, Liu et af. [ 1 45, 146] showed increased 
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metastatic potential in mice inheriting p53-RI72H (a murine p53 mutant homologous to 
the human p53-RI 75H). Using a murine p53-RI 72H mutant transgenic model system 
Wang et a/. [ 1 24, 1 40] showed some evidence of gain-of-function associated with 
genomic instability and Murphy et a/. [ 1 42] reached similar conclusions using the same 
p53 mutant in a mammary epithelial murine cell model. Hixon et al. [ 1 47] proposed that 
cells carrying mutant p53 over-express Cks I ,  a protein that mediates activating 
phosphorylation of the anaphase promoting complex (APC) by cdc2 leading to 
chromosomal instability as cells are unable to sustain APC inactivation. More recently, 
clear and strong evidence of mutant p53 gain-of-function has been demonstrated in two 
mouse models of the Li-Fraumeni Syndrome where higher metastatic spread and/or 
different tumor spectrum have been observed in the presence of mutant p53 [ 1 48, 149]. 
Mechanisms of mutant p53-mediated gain-of-function. Mutant p53 may achieve 
gain-of-function phenotypes by a direct acquisition of new functions actively involved in 
proliferation processes [ 1 1 9]. Two possible models have been proposed to explain the 
molecular mechanism underlying mutant p53 gain-of-function. 
The first, involves transcriptional modulation by mutant p53 of specific target genes. 
For example, mutant p53 may transactivate growth promoting genes, disrupt DNA repair 
or apoptotic activities or even inhibit growth suppressive genes [ 1 50- 1 52]. It has been 
shown that mutant p53 can transactivate promoters of growth-related genes in vivo, even 
in the absence of WTp53, such as human proliferating cell nuclear antigen (PCNA), 
epidermal growth factor receptor (EGFR), interleukin 6 (IL-6), multiple drug resistance I 
(MDRl), basic fibroblast growth factor (BFGF) and c-myc among others [reviewed in 
[85, 1 19], [1 1 ,  120, 134, 1 53-155]]. The sequence requirements for mutant p53-mediated 
transactivation of these genes is independent of a p53 DNA binding consensus and it is 
believe that mutant p53-mediated regulation of these promoters is through its interaction 
with other factors. Structure-function analyses indicate that the d9main requirements for 
transactivation by WT and mutant p53 are different and that mutant p53 does not require 
a WTp53 DNA binding site [133, 134, 1 55, 1 56]. It is recognized that mutant p53 
requires both its amino and carboxy termini for gain-of-function [ 1 33, 134]. A 
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transactivation deficient fonn of mutant p53-D281 G that incorporates two additional 
mutations within the transactivation domain [p53-D281 G (L22Q/W23S)] that disrupt 
T AF interactions and c-tenninal modifications can no longer transactivate the MDR 1 and 
c-myc promoters [ 1 33, 1 54]. More importantly, this transactivation deficient mutant 
failed to confer tumorigenic potential in p53-null fibroblasts [ 1 33]. Taken as a whole, 
modulation of gene expression by mutant p53 in oncogenesis remains largely 
uninvestigated (Figure 3). 
Figure 3. Differences between mutant and WTp53. 
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The second model explaining mutant p53-gain-of-function involves protein-protein 
interactions between mutant p53 and other cellular protein(s) such as the p53 family 
members, p73 and p63, DNA repair machinery proteins, and/or proteins of the apoptotic 
pathway in the cytoplasm and/or mitochondria [ 1 57, 1 58]. The proteins p73 and p63 
have structural and functional similarity with p53, and have been shown to transactivate 
promoters containing p53-binding sites [ 1 59- 1 62]. Like WTp53, p73 can also induce 
apoptosis or growth suppression of cells expressing elevated levels of the protein [ 1 59-
1 62]. Over-expression of p73 in different cancer cell lines has been detected, providing 
evidence that p73 may substitute for WTp53 as a tumor suppressor in cells lacking 
expression of p53 altogether [ 1 63, 1 64]. Tumor-derived mutant p53 may inactivate the 
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physiological functions of p73 (or p63) through hetero-oligomerization. Evidence of this 
phenomena exists in the literature ( 1 59, 1 60]. It is possible then that at least part of the 
oncogenic effect of mutant p53 arises from an interaction of the mutant protein with 
endogenous p73 (or p63). This interaction, however, is affected by a common p53 
polymorphism at residue 72 (R vs. P) where a R 72 form is more likely to interact with 
p73/p63 than the P72 form of p53 [ 1 65, 1 66]. Using isogenic cell lines expressing 
various p53 mutants in their R 72 or P72 form, Bergamaschi et al. ( 1 67] showed that 
those mutants expressing the R72 form were more resistant to chemotherapy. 
Interestingly, the mutant background used in this study is P72. 
The gain-of-function properties of mutant p53 may also be dependent on protein­
protein interactions other than p53/p76-p63 interactions. A number of proteins have been 
identified that specifically interact with either WT or mutant p53 ( 1 1 9]. Mutant p53 
binding protein I or MBP I ,  an oncogenic protein, has been found to interact with p53-
RI75H and other p53 mutants but not with WTp53 [ 1 68]. There is also evidence to 
indicate that mutant p53 may promote homologous recombination [53; 1 4 1 ]. WT and 
mutant p53 also interact differently with MDM2 ( 1 69]. Interestingly, the central DNA­
binding domain of mutant p53 and not of WTp53, binds to MDM2. It is not clear, 
however, whether this interaction has any impact on gain-of-function. 
Although major emphasis has been given on the transcriptional function of WTp53, 
functions independent of transcription have also been described [ 1 70- 1 74]. For example, 
Mihara et al. ( 1 58] demonstrated a direct apoptogenic role of WTp53 at the 
mitochondria, independent of its transcriptional activity. Chipuk et al. ( 1 70] also showed 
a transcription-independent apoptotic role of WTp53 that may initiate in the cytoplasm. 
The impact of mutant p53 on these processes, if any, is unknown. Ohiro et al. [ 1 75] 
showed that mutant p53 inhibits stress-inducible kinase pathways, and demonstrated its 
anti-apoptotic activity. This activity was also independent of the transactivation function 
of mutant p53. 
The two proposed models are not mutually exclusive and the most likely scenario is 
that mutant p53 disrupts cellular functions by both transcription-dependent and -
II 
independent mechanisms. Future proteomic analysis in conjunction with functional 
assays will lead to a clarification of the role of protein-protein interactions in gain-of­
function. 
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I. Chapter 2. Hypothesis 
a. Major hypothesis. 
The major hypothesis of this work was: Mutant p53 up-regulates specific genes 
leading to gain-of-function properties and oncogenicity of cells expressing mutant p53. 
This up-regulation of genes is transactivation dependent contributes to gain-of-function 
properties of mutant p53. 
This hypothesis was based on the following observations. Experiments with WTp53 
in which the tetramerization domain had been replaced by a heterologous dimerization or 
tetramerization domain have shown that the heterologous oligomerization domain 
preserves wild-type p53-mediated transactivation and growth suppression (including GIIS 
inhibition) functions [ 1 76- 1 80]. However, no information was available regarding the 
consequences of replacing the oligomerization domain of tumor-derived p53 mutants. 
Using murine non-tumorigenic p53-null 10(3) cells, it had been shown that expression of 
tumor-derived p53 mutants such as p53-D281 G, -R1 75H and -R273H increase the 
tumorigenicity of the cells in nude mice remarkably [ 1 33, 1 34]. Further experiments 
demonstrated that the transactivation function of p53 mutants was required for its 
oncogenic function [ 1 33, 1 34]. Blandino et af. [ 1 28], reported that mutant p53 
expression (in cells devoid of WTp53) can lead to decreased sensitivity against 
chemotherapeutic drugs such as doxorubicin, etoposide, cisplatin. Other groups have 
reported similar results [ 1 26, 1 37, 1 38, 1 8 1 - 1 86]. Several other gain-of-function 
phenotypes have been reported [ 1 33- 1 43], yet, the exact role of transactivation, if any, 
had not examined in detail. Finally, evidence in the literature suggested that 
transactivation played a role in mutant p53 tumorigenicity. As such, it was important to 
identify target genes modulated by mutant p53 in the absence of WTp53. It was 
hypothesized that this type of analysis would reveal a set of target genes whose 
transcriptional modulation by mutant p53 would explain the gain-of-function phenotypes 
observed. 
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b. Specific Aims. 
The following are the specific aims: ( 1 )  To determine whether the oligomerization 
domain and C-terminally located sequences are necessary for transactivation and gain-of­
function properties of mutant p53; (2) To determine whether mutant p53 requires its 
transactivation function to induce gain-of-function properties; and (3) To identify genes 
modulated by tumor-derived p53 mutants. 
J. Chapter 3. 
Hetero-oligomerization does not Compromise Mutant p53 
Gain-of-Function. 
1 4  
The work presented in this chapter has been published in the Oncogene research journal (Oncogene. 
2002 Jan 1 0;21 (2): 176-89.). CAT assays and 35S immunoprecipitations were performed by D Deb, QPCRs 
by KE Roth and colony forming and tumorigenicity assays by AS Chakraborti. 
a. Introduction. 
Replacement of the oligomerization domain of WTp53 with a heterologous 
dimerization or tetramerlzation domain showed that it could preserve WTp53-mediated 
transactivation and growth suppression functions [ 1 76, 1 77, 1 79, 180, 1 87]. Similar' 
experiments showed that the gain-of-function phenotype of tumor-derived p53 mutants 
also required the C-terminally located oligomerization/nucleic acid-binding domain 
[ 1 34]. However, no information was available regarding the consequences of replacing 
the oligomerization domain of tumor-derived p53 mutants and whether the C-terminal 
regions are only required for oligomerization or have other function(s) necessary for 
mutant p53-mediated transactivation and/or gain-of-function. 
b. Experimental Results. 
Replacement of the tetramerization domain inhibits mutant p53-mediated 
transactivation. Earlier, this laboratory had shown that several tumor-derived p53 
mutants could transactivate promoters of a number of growth-related genes including the 
EGFR gene promoter [153, 1 55]. However, the deletion mutant p53-D281 G  del. 393-
327, which eliminates the oligomerization domain of the protein, failed to transactivate 
the promoter [ 1 55], suggesting that proper oligomerization of a tumor-derived p53 
mutant is required for the transactivation function of the mutant protein. 
Therefore it was necessary to determine if the C-terminally located 
oligomerization/non-sequence-specific nucleic acid binding domain is required only for 
oligomerization. It was shown earlier that replacement of the tetramerization domain of 
WTp53 by a ditnerization domain consisting of the coiled-coil structure from the yeast 
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GCN4 protein (or a derivative of the coiled-coil structure that results in a tetramerization 
domain) could effectively sustain wild-type p53-transactivation and growth suppression 
functions [ 1 76, 1 80, 1 87]. Performing similar experiments, p53-D281 G derivatives with 
such a replacement of the tetramerization domain would be predicted to retain the 
transactivation function. 
The effect of expression of p53-D281 G, p53-D28 1 G 343cc (the coiled-coil structure 
from GCN4 is placed after the amino acid 343) [ 1 78] and p53-D28 1G TZ334NR (a 
modified GCN4 coiled-coil structure is placed after amino acid 334 such that it functions 
as a tetramerization domain) [ 1 80] on the activity of the EGFR promoter was studied 
(Figure 4). Transfections were carried out in p53-null Saos-2 cells. 
The results shown in Figure 5 from luciferase assays demonstrate that p53-D28 1 G­
mediated transactivation of the EGFR promoter is not preserved by replacing its 
tetramerization domain by a heterologous dimerizationltetramerization motif. This 
suggests that this region performs some vital function(s) required for mutant p53-
mediated transactivation that cannot simply be substituted by a heterologous 
dimerizationltetramerization domain. Amino acid residues 320-360 of p53 code for the 
tetramerization domain [ 1 6, 23, 28, 1 88]. Besides partial substitution of this domain 
(starting from residue 334), the C-terminal amino acids past the oligomerization in p53-
D28 1 G  TZ334NR have been deleted (residues 352-393). This segment may also play an 
important role in mutant p53-mediated transactivation. 
Figure 4. Schematic representation of p53-D281 G oligomerization derivatives. 
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The mutant p53-D281 G TZ334NRI352, having the sequences 352-393 inserted 
following the TZ moiety was also tested. This mutant transactivated the best among all 
the domain replacement mutants. The western blot analysis shows equivalent amounts of 
expression by p53-D28I G and p53-D281 G TZ334NR, thus an expression deficiency 
cannot explain the inability of p53-D281 G TZ334NR to transactivate. The experimental 
results suggest that the C-terminally located amino acids 352-393 perform a vital function 
for mutant p53-mediated transactivation since transactivation by this mutant was 4 fold 
over that of p53-D281 G TZ334NR. Earlier, a similar conclusion was reached by Frazier 
et a/. [ 1 54], demonstrating a requirement for amino acids 370-380 for transactivation of 
the c-myc promoter by p53-D28I G. Similar experiments were carried out using WTp53 
(data not shown). Replacement of the oligomerization domain of WTp53 did not affect 
the transactivation ability of the protein in agreement with earlier studies (data not 
shown) [ 1 76, 1 77, 1 79, 1 80, 1 87]. 
Figure 5. Replacement of the tetramerization domain of mutant p53 has a drastic 
effect on mutant p53-mediated transactivation. 
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Replacement of the tetramerization domain of mutant p53 preserves 
tetramerization of the protein. One possible reason for the failure of p53-D281 G 
TZ334NR and p53-D281 G  TZ334NRI352 to transactivate the EGFR promoter efficiently 
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could be a defect in oligomerization. Using a glutaraldehyde cross-linking assay, the 
ability of the mutant p53 to form tetramers was tested as described [23]. The various 
mutant p53 forms were synthesized using 35S-labeled methionine and an in vitro 
transcription-translation system. The synthetic proteins were incubated with 
glutaraldehyde at varying final concentrations (Figure 6). After cross-linking, the protein 
oligomers were analyzed using a gradient (4-20%) sodium dodecyl sulfate (SDS)­
polyacrylamide gel electrophoresis (SDS-PAGE). 
Figure 6. Replacement of the tetramerization domain of mutant p53 preserves 
tetramerization of the protein. 
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The data shown in Figure 6 indicates that p53-D281 G, p53-D281 G  TZ334NR1352 
and p53-D281G TZ334NR oligomerized, while p53-D281G del 393-327 could not, 
although there is some variation in tetramerization among p53-D281 G, p53-D281 G 
TZ334NR1352 and p53-D281 G  TZ334NR. Since p53-D281 G  TZ334NR1352 and p53-
D28 1 G  TZ334NR are capable of oligomerization into tetramers, the results shown in 
Figure 4 demonstrate that the C-terminally located oligomerization/nucleic acid binding 
domain is required for p53-D281 G-mediated transactivation. 
Transactivation of the EGFR and MDRI promoters by the tumor-derived 
mutant p53-D281 G  is inhibited by co-expression of p53 del. 1 -293. Hetero­
oligomerization of WTp53 with miniproteins containing only the C-terminal 
oligomerization domain results in inactivation of WTp53 function ( 1 89]. Therefore, it 
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was also necessary to investigate if such an interaction would inactivate mutant p53 
mediated transactivation. Saos-2 cells were co-transfected with EGFR.Luc [ 1 55] or 
MDRl.CAT (chloramphenicol acetyl transferase) [ 1 33, 1 90], an expression plasmid for 
p53-D28 1 G (or vector alone) and an expression plasmid for p53 del. 1 -293 (or vector 
alone). 
Figure 7. Transactivation of the EGFR promoter by tumor-derived mutant p53-
D28 1 G  is inhibited by co-expression of p53 del. 1 -293. 
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Figure 8. Transactivation of the MDRI promoter by tumor-derived mutant p53-
D28 1 G  is inhibited by co-expression of p53 del. 1 -293. 
� 500 
.£ 400 
-! 
'" 300 « 
f-
« 200 u 
.. 
-! 100 .!I 
.. 
IX 
0 
Vector 
MDR1.CAT 
p53-281G 
Lane I 
p53-281 G � 
p53 del 1-293 � 
p53 del \-293 p53-281G and 
p53 del 1-293 
2 kD -60 
-18 
-14 
Transfections, CAT and luciferase assays were carried out as described in Materials 
and methods. Figures 7 and 8 show the results of the assays; it is apparent that although 
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the tumor-derived p53-mutant transactivated the EGFR and MDRI promoters, this 
transactivation was significantly reduced by the co-expression of p53 del. 1 -293. 
Western blot analyses examining expression of the two proteins from a representative 
experiment demonstrates that the proteins were adequately expressed; thus, lack of 
transactivation by p53-D281 G  in the presence of p53 del. 1 -293 cannot be explained by 
protein expression deficiencies. It is possible then that hetero-oligomers between p53-
D281 G and p53 del. 1 -293 are inactive in transactivation. 
p53 del. 1-293 complexes with p53-D281G in vivo. Since co-expression of p53 del. 
1 -293 reduced mutant p53-D281 G transactivation it was necessary to check whether 
these two proteins interacted in vivo. Saos-2 cells were co-transfected with expression 
plasmids for p53-D281 G  (or vector alone) and p53 del. 1 -293 (or vector alone) into Saos-
2 cells. Twenty-four hours after transfection, cells were labeled in vivo by 35S_ 
methionine. Cell extracts were prepared and used in immunoprecipitations (Figure 9). 
Immunoprecipitations were perfonned using an antibody specific for the N-tenninus 
of mutant p53 (Ab DOl ,  Figure 9). Western blot analysis was conducted using an 
antibody against the C-tenninus of p53. Although the antibody DOl could not 
immunoprecipitate p53 del. 1 -293 alone (Figure 9, lane 4), it could precipitate the 
deletion mutant in the presence of p53-D281 G (Figure 9, lane 3). This shows that p53 
del. 1 -293 binds with p53-D281 G  in vivo fonning a hetero-oligomeric complex. Thus, 
results of these experiments (Figures 6-8) suggest that proper oligomeric fonns of p53-
D281 G are necessary for its transactivation function. 
Figure 9. The protein p53 del. 1 -293 co-immunoprecipitates with p53-D281 G. 
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Co-expression of p53 del. 1-293 inhibits the endogenous transactivation by p53-
D281 G. Hetero-oligomerization of wild-type p53 with tumor-derived p53 mutants (or 
polypeptides covering the oligomerization domain of p53) inhibits wild-type p53 
biological functions leading to immortalization and transformation of rat embryo 
fibroblasts [ 1 89]. Since co-expression of p53 del. 1 -293 and p53 (wild-type or mutant) 
inhibited p53 transactivation [ 1 9 1 ], it was important to test whether hetero­
oligomerization between p53-D281  G and p53 del. 1 -293 would lead to inhibition of 
transactivation of endogenous genes by p53-D28I G. 
To identify genes endogenously transactivated by p53-D28 1 G, p53-null murine 1 0(3) 
cells stably transfected with p53-D28 1 G were compared with cells stably transfected with 
vector (pCMVBarnNeo, Hinds e/ al., 1 990) alone by microarray hybridization analysis 
(lncyte Genomics). The analysis identified a number of genes expressed at a higher level 
in p53-D281  G expressing cells with a fold difference in expression of two or more. Two 
such genes, PCNA and NF-KB2, were chosen to see the effect of co-expression of p53 
del .  1 -293 . Quantitative real time PCR (QPCR) analysis of cDNA made from total RNA 
shows that the levels of both the genes are considerably higher in 1 0(3) cells expressing 
the mutant p53-D28 1 G  compared to that in cells stably transfected with vector alone 
(Figure 1 0). 
Figure 10. Co-expression ofp53 del. 1 -293 inhibits transactivation by p53-D28 1 G. 
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Furthermore, co-expression o f  p53 del. 1 -293 decreased the level of the RNAs to 
some extent suggesting that hetero-oligomerization indeed inhibits transactivation by 
mutant p53. Interestingly, 1 0(3) cells expressing p53 del. 1 -293 expressed more of the 
two RNAs compared to vector-transfected cells. A possible explanation for these results 
may be that mutant p53 transactivates these genes through a synergistic interaction with 
another transactivation factor after localization of the complex on or near regulatory 
regions of the genes. Since p53 del. 1 -293 does not posses a transactivation domain, the 
observed up-regulation may be due to that second transactivating protein. This 
possibility also suggests that the interacting factor binds/interacts with mutant p53 at its 
C-terminus. 
p53 del. 1-293 did not inhibit colony formation by p53-D281G. Expression of 
p53-02 8 1  G also gives growth advantage to cells expressing the mutant protein [ I I ] . It 
was therefore necessary to determine whether p53 del. 1 -293 expression could influence 
the growth advantage conferred by mutant p53 . Using a colony formation assay to assay 
for cell proliferation, 1 0(3) cells stably expressing the expression vector (pCMYBam 
NEO) alone or expression plasmid for p53-028 1 G were transfected with the following 
expression plasmids: ( I )  pCMYBam and pHyg, (2) pCMYBam p53 (wild-type) and 
pHyg, (3) pCMYBam FLAG-p73a and pHyg, (4) pCMYBam p53 del. 1 -293 and pHyg. 
The data presented in Table 1 indicates p53-02 8 1  G expressing cells have a discernable 
growth advantage over vector-transfected cells. The deletion mutant p53 del. 1 -293 had 
little effect, if any (compared to vector alone), on the growth properties of p53-028 1 G­
expressing cells. Co-transfection of the cells with WTp53 or p73a decreased the number 
of colonies formed substantially, as expected, since both WTp53 and p73a have been 
shown to be growth inhibitors when expressed in cells [2, 3 1 -4 1 , 1 92]. Thus, once again 
we find that del. 1 -293 could not significantly change the growth enhancing function of 
mutant p53 suggesting that hetero-oligomerization may not be enough to inhibit gain-of­
function. 
In an earlier report, it was shown that a deletion of the C-terminal sequences of p53-
028 1 G overlapping the oligomerization domain disrupts gain-of-function properties. 
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Here experimental data suggest that hetero-oligomerization disables transactivation by 
p53-D28 l G without eliminating gain-of-function properties (tumorigenicity). Taken 
together this information suggests that the C-terminal sequences have a separate role in 
gain-of-function in addition to that in transactivation. 
Table 1. Colony formation in 1 0(3) cells. 
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Vector alone, clone 4 pHyg and pCMYBam 0,0,2; avg. 0.67 
p53-D28IG, clone 4 pHyg and pCMYBam 1 37, 1 1 7, 132; avg. 1 29 
Vector alone, clone 4 pHyg and pCMYBam WTp53 4,0,0; avg. 1 .33 
p53-D28I G, clone 4 pHyg and pCMVBam WTp53 4,2 1 ,5 ;  avg. 1 0  
Vector alone, clone 4 pHyg and pCMYBam p73a 3,8,38; avg. 1 6.33 
p53-D28IG, clone 4 pHyg and pCMYBam p73a 0,8, 1 8 ; avg. 8.67 
Vector alone, clone 4 pHyg and pCMYBam p53 del. 1 -293 1 ,4,0; avg. 1 .67 
p53-D28I G, clone 4 pHyg and pCMYBam p53 del. 1 -293 1 13,1 25,107; avg. 1 1 5 
Co-expression of p53 del. 1-293 does not inhibit tumorigenicity of 10(3) cells 
expressing the mutant p53-D281G protein. It was important to test whether hetero­
oligomerization between p53 del. 1 -293 and p53-D28 1 G would lead to inhibition of 
tumorigenicity of mutant p53 expressing cells. Although 1 0(3) cells expressing p53-
D28 1 G  form tumors, cells stably expressing p53-D28 1 G  del. 393-327 (defective in 
oligomerization) do not [ 1 34]. This suggested a role for oligomerization in gain-of­
function. 
Stable cell lines were generated from 1 0(3) cells (I ) expressing p53-D28 1 G, (2) 
expressing p53 del. 1 -293, (3) expressing p53-D28 1 G  and p53 del. 1 -293 and (4) stably 
transfected with vector alone [ 1 0(3) V4]. Cells were checked for expression by western 
blot analysis (data not shown). Two different clones from each stable transfection were 
injected subcutaneously into two or three different nude mice (two sites on each mouse) 
as described in Materials and methods. The mice were then observed for several weeks 
for appearance of tumors. 
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As shown in Table 2, 1 0(3) cells stably transfected with pCMVBam vector alone or 
stably expressing p53 del. 1 -293 did not show any tumor formation even after five 
months. In cells expressing p53-D28 1 G and p53 del. 1 -293 tumors appeared within 1 -2 
weeks of injection; a similar situation was observed with 1 0(3.) cells expressing p53-
D28 1  G alone. Since co-expression of p53 del. 1 -293 and p53-D281  G did not reduce 
tumorigenicity, hetero-oligomerization may not interfere with mutant p53-mediated 
tumorigenesis. 
Table 2. Twnorigenicity of 1 0(3) cells expressing p53 derivatives. 
Vector alone, clone 2 2/4 0/4 
Vector alone, clone 2 1  2/4 0/4 
p53 del. 1-293, clone 1 7  2/4 0/4 
p53 del. 1-293, clone 1 9  3/6 0/6 
p53-D281 G, clone 13 3/6 6/6 
p53-D281 G, clone 4 2/4 4/4 
p53-D281 G, clone 4 and 3/6 6/6 p53 del. 1 -293 cloDe 22 
p53-D281 G, clone 4 and 3/6 6/6 
p53 del. 1 -293, clone 1 0  
Hetero-oligomers are produced between p53-D281G and p53 del. 1-293 in  10(3) 
cells. Since co-expression of p53-D28 1 G  and p53 del. 1 -293 in 1 0(3) cells did not 
interfere with tumorigenicity, in vivo complex formation between these two proteins 
needed to be confUTned. Extracts from 1 0(3) cells expressing the p53 del. 1 -293 
deletion mutant alone and cells expressing p53-D28 1 G  and p53 del. 1 -293 were prepared 
and immunoprecipitation reactions carried out as described in Materials and methods. 
lmmunoprecipitations were performed with the antibody DO I .  The immunoprecipitates 
were separated by SDS-PAGE, and proteins transferred to a nitrocellulose membrane. 
The blot was then developed with PAb42 1 antibody. The data shown in Figure I I  show 
that DO l immunoprecipitates both p53-D28 1 G  and p53 del. 1 -293 indicating that hetero-
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oligomer formation between the two proteins occurs. As expected, DO 1 did not 
immunoprecipitate p53 del. 1 -293. 
Figure 1 1 .  Hetero-oligomers are produced between p53-D281  G and p53 del. 1 -293 in 
1 0(3) cells stably expressing the two proteins. 
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It was hypothesized that the C-terminal sequences for mutant p53 would be required 
for oligomerization, and oligomerization may be critical for gain-of-function. An N­
terminal deletion mutant of p53 that deletes amino acids 1 -293 was used as a tool to 
perform hetero-oligomerization studies. This mutant retains the entire oligomerization 
domain but dispenses of the transactivation domain and a large portion of the sequence-
specific DNA-binding domain. Co-transfection experiments followed by 
immunoprecipitation showed that p53 del. 1 -293 forms hetero-oligomeric complexes 
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with p53-D28 1 G. Also, co-expression of p53 del. 1 -293 inhibited p53-D28 1 G-mediated 
transactivation of the EGFR and MDRI promoters suggesting that hetero­
oligomerization inactivates transcriptional functions of mutant p53 .  The interaction of 
p53 del. 1 -293 and p53-D28 1 G  reduced transactivation potential of p53-D28 1 G  in stably 
transfected 1 0(3) murine cells. Although 1 0(3) cells stably transfected with p53-D28 1 G  
expressed 5-6-fold more peNA and NF-KB2 mRNA compared to the cells transfected 
with vector alone, co-expression of p53 del. 1 -293 reduced this up-regulation 
considerably. Therefore, the data presented supports the idea that proper oligomeric 
forms of mutant p53 are required for its transactivation function. The transactivation data 
generated supports this idea, yet tumorigenicity and colony formation assays show that 
co-expression of the deletion mutant in the presence of p53-D281  G does not inhibit gain­
of-function by mutant p53 .  Thus, hetero-oligomerization between p53-D281  G and p53 
del. 1 -293 may not completely inhibit p53-D28 1 G growth enhancing properties, although 
it does inhibit its transactivation ability. 
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K. Chapter 4. 
Role of Transactivation in Mutant p53 Gain-of-Function Properties. 
The work presented in this chapter has been published in the journals Oncogene and Cancer Research 
(Oncogene. 2002 Jan 1 0;2 1 (2): 176-89. and Cancer Res. 2004 Oct 1 5 ;64(20):7447-54). 
a. Introduction. 
Using murine non-tumorigenic p53-null 1 0(3) cells it had been shown that expression 
of tumor-derived p53 mutants such as p53-D281  G, -R1 75H and -R273H increase the 
tumorigenicity of the cells in nude mice remarkably [ 1 33, 1 34]. Further experiments 
demonstrated that the transactivation function of p53 mutants was required for its 
oncogenic function [ 1 33 ,  1 34]. 
Blandino et at. [ 1 26, 1 28, 1 37, 1 38, 1 8 1 - 1 86], reported that mutant p53 expression (in 
cells devoid of WTp53) can lead to decreased sensitivity to chemotherapeutic drugs such 
as doxorubicin, etoposide, cisplatin and other groups have also reported similar results 
[ 1 26, 1 28, 1 37, 1 38, 1 8 1 - 1 86]. Several other mutant p53 gain-of-function phenotypes 
have been described in the literature [ 1 33- 1 43] ,  yet the exact role of transactivation, if 
any, was not examined. Here, the role of transactivation was examined in three gain-of­
function phenotypes (growth rate, chemosensitivity and soft agar plating efficiency). 
b. Experimental results. 
Expression of tumor-derived mutant p53 in p53-null cells confers a growth 
advantage. In order to explore the role of mutant p53 mediated transactivation in the 
various gain-of-function phenotypes it was first necessary to detennine if the p53 mutants 
available in the laboratory could induce any gain-of-function. A series of p53 mutants 
found in human cancers were selected for the initial studies. For example, mutations at 
amino acid 1 75 account for 5 .09% of all p53 mutations found in human cancers and 
mutations at 273 for 6.49% I .  Using the colony assay described [ 1 56] we co-transfected 
I Data has been adaptedfrom p53 Database (http://p53. curie.frI). Percentages are calculated with respect 
to the total p53 mutations reported/or all human cancers. 
27 
1 0(3) cells with pCMV-Bam Neo and pCMV-Bam p53 (WT or mutant) or pCMV-Bam 
expression vector. Forty-eight hours after transfection the cells were subcultured and 
grown in selective media with periodic changes in media every three or four days. After 
three to four weeks of selection the cells were stained and colonies were counted. If p53 
confers growth advantage and aids in transformation in 1 0(3) cells they should multiply 
faster than the vector transfected cells leading to an increased number of neomycin 
resistant colonies. 
Co-expression of WTp53 with the pCMV -Bam Neo vector, as expected, reduced the 
number of colonies formed when compared to vector transfected cells (Figure 1 2). In 
contrast, cells transfected with mutant p53 showed an increased number of colonies 
formed, ranging from no change at all (i.e. p53-HI 79Y) to two- (i.e. p53-RI 75H) or 
three- (i.e. p53-D28 1 G) fold increase, indicating that expression of most of the p53 
mutants confers a growth advantage on the cells. Mutant p53-D28 1 G formed the highest 
number of colonies compared to any of the other p53 mutants examined. 
Figure 12. Expression of tumor-derived mutant p53 increases the formation of 
neomycin resistant colonies. 
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Tumor-derived p53 mutants do not bind the p53 consensus site. WTp53 function 
is largely dependent on the ability of the protein to bind DNA and act as a transcriptional 
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activator. It can bind to a consensus sequence that contains two copies of a 10 base pair 
motif 5'-PuPuPuCWWGPyPyPy-3' separated by O- 1 3bp ( 1 93] .  Consequently, mutations 
in the DNA-binding domain of the WT protein would result in the inability of the mutant 
protein to bind DNA. 
Figure 13. DNA binding of WT and tumor-derived p53 mutants. 
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Electrophoretic mobility shift assays (EMSAs) were performed to study the ability of 
our p53 mutants to bind a p53 DNA-binding site. Assays were conducted using a probe 
containing the distal p53-binding site found in the p2 1 promoter to determine the ability 
of the p53 mutant to bind the WTp53 DNA consensus site [ 1 94] (Figure 1 3). 
Lanes 1 -5 were incubated with purified protein ( l OOng) [ 1 95] while lanes 6-23 were 
incubated with 1 0  Ilg of total protein from nuclear extracts generated after transfection of 
SAOS-2 cells with expression plasmids for the specified p53 protein. As expected 
WTp53 can bind the probe (lanes I ,  6-7) containing the p53-binding site (p2 1 WT). The 
same probe added in excess as a cold competitor (lanes 2-3, 8-9) diminishes the amount 
of protein binding observed, and a non-specific competitor (P2 1 MT) added in excess has 
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no effect in the binding (lanes 4-5, 1 0- 1 1 ). Addition of a p53 specific antibody (DO 1 )  
produces a supershift (lane 1 2). Under the same conditions, any of the twelve mutant p53 
species tested were unable to bind the binding site containing probe (lanes 1 4-23). 
Similar results were obtained using a probe containing the consensus p53 sequence found 
in the Ribosomal Gene Cluster promoter (data not shown). 
Figure 14. Transcriptional activation of p53-inducible promoters by mutant p53 .  
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Since mutations in the p53-DNA binding domain can effectively obliterate DNA­
binding ability of the mutant p53 under the conditions of this assay, the question remains 
as to how some tumor-derived p53 mutants are capable of transactivating genes such as 
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MDR I ,  PCNA and c-myc, all of which are inhibited in the presence of WTpS3 .  These 
facts present the possibility that the transactivation observed is mediated through the 
actions of another transcription (or DNA binding) factor such as Spl or through direct 
binding of the mutant protein to a site of as yet unknown sequence. 
Mutant p53 does not transactivate or repress WTp53-regulated promoters. The 
tumor suppressor function of the pS3 protein is correlated with its ability to 
transcriptionally activate or repress gene expression [ I ,  2, 34]. Promoter assays were 
performed to examine the ability of the various tumor-derived pS3 mutants to 
transactivate targets of WTpS3 (i.e. p2 1 and MDM2). WTpS3 induced the p2 1 promoter 
by approximately 1 2-fold compared to the vector. The same amount of tumor-derived 
pS3 mutants was unable to elicit a response of such magnitude (Figure 1 4). Five of our 
mutants, pS3-V I 43A, pS3-V I S7F, pS3-Y I 63C, pS3-D28 I G, and pS3-R282W 
transactivated this promoter by at least 2-fold, suggesting that some mutants may have 
some residual WTpS3 activity or can transactivate this promoter using a different 
molecular mechanism. 
The effects of the pS3 mutants on the promoter of the human mouse double minute 2 
(MDM2) gene, another target of WTpS3 was also examined [34, 3S, 76] . As reported 
earlier, WTpS3 transactivated this promoter approximately SO-fold compared to the 
vector while most of our tumor-derived mutant pS3 proteins were unable to elicit any 
response (Figure 1 4) [ 1 96]. Mutant pS3-D28 1 G  and pS3-R282W transactivated this 
promoter a minimum of five to six fold, though this is 1 0-fold less than the 
transactivation observed with WTpS3 .  
Mutants of pS3 used in  this study were also analyzed for their ability to repress 
promoters normally inhibited by WTpS3 [34, 3S,  76, 1 34, I S3, 1 97] . For this purpose the 
SV 40 early promoter contained within the pGL2 vector (Promega) was used as a 
representative example. Again, as reported earlier [ 1 97], WTpS3 transcriptionally 
inhibited this promoter approximately 1 0-fold. The inhibitory effects of mutant pS3 
varied appreciably, pS3-RI7SH lost 1 00% of its inhibitory effects; while pS3-R273H and 
pS3-H 1 79Y lost approximately SO% (Figure I S). Interestingly, pS3-D28 1 G  
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transactivated this promoter. The reasons why this occurs are sti l l  unknown. For 
subsequent studies mutant p53-R 1 75H, -R273H and -0281  G were selected for use as 
models. The first two mutants were chosen as representative examples of structural 
(RI 75H) and contact (R273H) p53 mutants. The third, 028 1 G, was selected in order to 
correlate results with experimental data already avai lable in the l iterature. 
Figure 15. Transcriptional activation of p53-repressed promoters by mutant p53 .  
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H1299 cells expressing p53-RI 75H, -R273H and -D281G exhibit an increased 
growth rate. H 1 299 ( lung carcinoma) cells were used to generate stable transfectants 
expressing one of three p53 mutants (-RI 75H, -R273H and -0281  G). Additionally cells 
l ines expressing a transactivation deficient form, p53-R175H (L22Q/W23S) or p53-
D28 1  G (L22Q/W23S), were also generated. This mutant of p53 contains two additional 
mutations located within the transactivation domain of the protein [ 1 33] .  Expression of 
p53 was determined by western blot analysis (Figure 1 6). C lones expressing similar 
levels of p53 were selected for further experiments; asterisks in Figure 1 6  indicate clones 
used in microarray hybridization analyses. 21 PT (breast carcinoma) and Saos-2 
(osteosarcoma) cells expressing mutant p53 were also generated (data not shown). 
Earlier data indicated that expression of mutant p53 in cells normally devoid of p53 
may give a growth advantage [ 1 1 , 1 1 9, 1 34] .  This notion was tested using a growth rate 
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assay. Cells were plated at equal densities ( I  x l Os cells per plate); one plate of each cell 
line was seeded for each day of the assay. The data in Figure 1 7  show that mutant p53-
expressing H 1 299 cells proliferate at a higher rate compared to the vector control cell line 
(HC-5). This increased growth rate was also observed with different clones of H 1 299 
expressing the same p53 mutant and H 1 299 cells expressing different mutant p53 forms 
(R1 75H or R273H). At least two clones of each cell line were tested with similar results, 
decreasing the possibility that this characteristic is not due to a clonal variation (data not 
shown). 
Figure 16. Expression of mutant p53 in H 1 299 cells. 
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Expression of the transactivation deficient mutant p53-0281  G (L22Q/W23S) did not 
increase the growth rate of cells as well as those expressing p53-028 1 G. This mutant 
p53 is defective in gain-of-function as measured by the lack of increased tumorigenicity 
when constitutively expressed in 1 0(3) cells, which become tumorigenic if p53-0281  G is 
stably expressed in these cells [ 1 33] .  I t  has also been shown that this particular p53 
mutant is defective in transactivation of the MORI and c-myc promoters, which are up­
regulated by p53-028 1 G  [ 1 33 ,  1 34]. Since p53-D28 1 G  (L22QIW23S) is defective in 
transactivation, the lack of increased growth rate in cells expressing this mutant implies 
that transactivation is necessary for this gain-of-function property of mutant p53 . 
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RNAi against p53 decreases mutant p53 enhanced growth. To detennine whether 
expression of mutant p53 remains directly related to the increased growth rate in H l 299 
cells, we used p53-specific siRNA. H l 299 cells expressing p53-R1 75H were transfected 
with a double-stranded ribonucleotide sequence specific for p53 (or a non-specific 
sequence as a control) 24 and 4Shrs prior to plating [ 1 9S] .  Cell viability and level of p53 
were measured every day for up to five days after plating. Data presented in Figure I S  
show that as the mutant p53 protein level decreases after siRNA transfection ( l SA, days 
2-5), the number of viable cells remains similar to that of the control cells ( I SB, bottom 
panel, days 3-5). This continues up to day 5 ,  after which the transient effect of the 
siRNA diminishes. As the mutant p53 protein level begins to increase ( l SA, days 6-7), · 
cell viability also rises ( l SB, bottom panel, days 6-7), indicating that continuous mutant 
p53 expression is necessary for the observed phenotype. 
Figure 17. Mutant p53 expression results in enhanced growth rates in H 1 299 cells . 
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Thus, there is a direct relationship between mutant p53 level and growth enhancement 
in H 1 299 cells. Control siRNA itself does not affect mutant p53 mediated growth 
enhancement compared to vector control cells ( I 8B, upper panel). In a parallel 
experiment, levels of c-myc, a target of mutant p53, were examined after transfection 
with siRNA directed against p53 (Figure 1 8C). Western blot analysis shows that both 
p53 and c-myc levels decrease after transfection. Since the growth rate of mutant p53 
expressing cells decreases after siRNA treatment, this suggests a possible involvement of 
c-myc in mutant p53 mediated increased growth rate phenotype in H 1 299 cells. 
Figure 18. The increased growth rate phenotype is dependent on mutant p53 
expressIon. 
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81299 cells expressing mutant p53 show decreased sensitivity to etoposide. 
Earlier work by others has also shown that expression of mutant p53 in cells results in a 
decreased sensitivity to chemotherapeutic drugs [ 1 28] .  HI 299 cells stably expressing 
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p53-R I 75H, -R273H, -D28 1 G  (or transfected with vector alone) were tested for 
decreased sensitivity to etoposide using colony formation assay. Data shown in Figure 
1 9  indicate that cells expressing p53 mutants -RI 75H, -R273H and -D28 1 G are less 
sensitive to etoposide than the cells stably transfected with vector alone. This is in accord 
with results published by others using H 1 299 and other cell lines [ 1 28]. Expression of 
the transactivation deficient mutant p53-D28 1 G  (L22QIW23S) in H 1 299 cells did not 
affect chemosensitivity of the cells to etoposide. 
These results were recapitulated with H 1 299 pools and with 2 1 PT cell lines 
expressing the same three p53 mutants (Figure 20 and data not shown). Furthermore, a 
bromodeoxyuridine (BrdU) incorporation assay using the H 1 299 stable transfectants 
shows increased DNA replication in cells expressing mutant p53 (but not the 
L22Q/W23S transactivation deficient protein) after drug exposure (data not shown). 
Figure 19. Expression of mutant p53 in H 1 299 results in decreased sensitivity to 
etoposide. 
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As shown, cell lines expressing the transactivation deficient mutant p53 have a 
disadvantage in etoposide-induced cell death suggesting a correlation between mutant 
p53-mediated transactivation and the decreased chemosensitivity observed in cancer cells 
expressing p53 mutants. The mechanism behind this observation is unknown. This 
decreased ability of the cells to survive is perhaps due to the inability of the 
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transactivation deficient mutant to up-regulate genes whose expression provides cells 
protection against etoposide induce cell death. 
Figure 20. Pools of mutant p53-expressing H l 299 cells recapitulate results obtained 
earlier. 
H-lRES-RI 7 5 H  (L22QfW23S) pool 
H-lRES-RI 7 5 H  pool 
H-l RES-vector pool 
H-l RES-D28 1 G Pool •••••••••••••• II---l 
H-lRES-R273H pool 
H-l RES-RI 75H pool •••••••••• -t 
H-lRES-vector pool J�!.�--.-----r-----'�--'-- --'-----' 
o 20 40 60 80 100 1 20 140 1 60 
N u m be r  of colonies formed 
Mutant p53 enhances the plating efficiency of Saos-2 cells in soft agar. The 
ability of Saos-2 cells to form colonies in soft agar was assayed as described earlier by 
Dittmer e/ al. [ 1 1 ] .  Once again, a transactivation deficient mutant p53 expressing cell 
line was included in the assay. Saos-2 cells stably expressing mutant p53-D28 I G, p53-
D28 1  G (L22Q/W23S) or vector alone, were plated at a density of 3000 cells/well in 6-
well plates over a 0.5% agar plug: Cells were grown in 0.25% agar medium for 4-5 
weeks with periodic additions of media. Approximately I % of vector-transfected cells 
initially plated formed colonies, whereas mutant p53-D28 I G displayed an increased 
ability to grow in soft agar (5- 1 0% above vector control cells). Cells expressing mutant 
p53-D281  G (L22QIW23S) had a comparative growth of 2-3% (Figure 2 1 ). Additionally, 
colonies of cells expressing mutant p53-D28 1 G were larger (approximately 3-4 fold) than 
those formed by either vector or p53-D28 I G  (L22Q/W23S) expressing cells (data not 
shown). Although, mutant p53 enhances the plating efficiency of Saos-2 cells, 
expression of the transactivation deficient mutant did not completely reduce plating 
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efficiency. This suggests that for this gain-of-function phenotype, transactivation may 
not be the only factor involved. 
Figure 2 1 .  Mutant p53-expressing Saos-2 cells exhibit increased plating in soft agar. 
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Expression of mutant p53 resulted in increased growth rate (H 1 299 cells), decreased 
chemosensitivity (H1 299 and 2 l PT cells) and increased plating efficiency (Saos-2 cells). 
Expression of a transactivation deficient mutant p53 did not induce gain-of-function 
properties (increased growth rate and decreased chemosensitivity). This supports the idea 
that genes transactivated by mutant p53 may be responsible for these two gain-of­
function phenotypes. 
Unlike the other gain-of-function properties tested, soft agar plating efficiency in 
Saos-2 cells was not significantly affected by the expression of the transactivation 
deficient mutant, suggesting that transactivation may not be the only factor affecting this 
gain-of-function property. Perhaps this property is the result of both altered protein­
protein interactions and transactivation. 
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L .  Chapter 5. 
Modulation of Gene Expression by Tumor-Derived Mutant p53. 
The work presented in this chapter has been published in the journals Oncogene and Cancer Research 
(Oncogene. 2002 Jan 1 0;2 1 (2): 176-89. and Cancer Res. 2004 Oct 1 5;64(20):7447-54). 
a. Introduction. 
Since the data described above and earlier suggested that mutant p53-mediated 
transactivation is necessary for its growth promoting functions, gene expression profiles 
analyses were conducted using the H I 299 cell clones expressing mutant p53-RI 75H, -
R273H, or -D28 1 G in order to identify a possible pathway used by the mutant p53 
proteins in inducing oncogenesis [ 1 1 9, 1 33 , 1 34] .  
b. Experimental results. 
Mutant p53-RI75H, -R273H and -D281G expression in H1299 cells affects a 
common set of genes, including a number of growth-related genes. The gene 
expression profile of vector transfected HI 299 cells was used as controls. Affymetrix 
U95Av2 arrays (HG-U95Av2) were used for the analyses. Hybridization signals were 
normalized and filtered and changes in gene expression were detected in terms of S-score 
for a given gene between two compared microarrays [ 1 99, 200) . The magnitude of the S­
score represents the significance of change, thus an absolute value S-score greater than 2 
represents a p-value < 0.045, uncorrected for multiple comparisons. Scatter plot analyses 
(Figure 22) of the S-scores show a very high degree of consistency of changes in gene 
expression between biological duplicates. The scatter-grams also indicate a relatively 
large number of changes in gene expression in each of the mutant p53-expressing cell 
lines versus the control cell lines. 
In order to identify genes reproducibly affected by the expression of any mutant p53 
in these cell lines, the S-score data was analyzed by a permutation method computer 
program, Significance Analysis of Microarray (SAM) [20 1 ] .  A SAM analysis of the S­
scores has the advantage that small and subtle consistent changes reproduced across the 
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array samples can be detected. A one-class analysis and a stringent False Discovery Rate 
(FOR) of 0.3% were used so as to focus on the most reproducible changes evoked by the 
p53 mutant across all hybridizations. One-hundred and eight (88 up-regulated, 20 down­
regulated) genes were identified as having an altered expression in the mutant p53-
expressing cell lines. We found no WTp53 regulated genes such as p2 1 ,  MDM2, PUMA, 
DDB2, ERCC5, GADD45 or Bax [37, 38] included in the list. On the other hand, c-myc 
and PCNA, which have been reported as up-regulated by mutant p53, were present in our 
list of up-regulated genes. MDR l ,  BFGF, IL-6 and Bcl-2 were up-regulated minimally 
and therefore are not included in our final list of genes [ 1 1 9, 1 53, 1 56, 1 90, 202, 203) .  
Figure 22. Scatter-gram analysis o f  S-scores generated. 
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This type of analysis excludes those genes differentially affected by the p53 mutant 
proteins, therefore, a cluster analysis of this list only reveals two major clusters 
containing genes that are up-regulated or down-regulated in common by al1 three p53 
mutants (Figure 23). In paral1eJ, microarray data obtained from H 1 299 cel1s infected 
with adenovirus expressing WTp53 (or p-galactosidase control) were analyzed in a 
similar manner (data not shown) and compared to the transcriptional profiles from the 
mutant p53 expressing cel1 lines in order to determine the transcriptional response of the 
genes in the presence of WTp53. Table 3 shows a representative example of the genes 
identified as up-regulated in H 1 299 grouped in functional categories such as metastasis 
(i.e. human myeloid cell differentiation protein or MCL 1 ), cel1 cycle (i.e. ASNS and 
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E2F-5) [204, 205] ,  amino acid homeostasis (i.e. ASNS) [204] , transcriptional regulation 
(i .e. Nuclear Factor-IL6) [206, 207], and cell survival (i.e. NF-KB2) [208, 209] . Among 
the identified targets were the ASNS [204, 2 1 0-2 1 2] and the transcription factor NF­
KB2 [208, 209] .  Asparagine is a non-essential amino acid that has been reported as 
regulating expression of genes involved in cell growth [2 1 1 , 2 1 2] .  Depletion of 
asparagine can result in apoptosis and treatment of cancer with Asparaginase (ASNase), 
an enzyme used in combination chemotherapy, can reportedly induce an apoptotic 
response presumably through depletion of asparagine and asparagine synthetase 
expression alone has been found to be sufficient to induce ASNase resistance in cells 
[2 1 3, 2 1 4] .  The transcription factor NF-KB2, on the other hand, has been implicated in 
cell survival and chemoresistance, presenting a role for NF-KB2 [208, 209] . 
Figure 23. Expression of mutant p53 in H 1 299 changes the cellular transcriptional 
profile. 
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Table 3 .  Representative example o f  genes up-regulated by mutant. 
Function Gene Name Gene ban k  No. S-score Effect by value WTp53 
glycyl-, threonyl-, U095 1 0; 5.248; 
Amino acid and asparaginyl -tRNA synthetases 
M63 1 80; 3 .69 1 ;  Repressed 
Protein Synthesis 
084273 2.880 
Asparagine synthetase* M27396 5 .07 1 Repressed (ASNS) 
Cyelin H UI1 79 1  2.035 Repressed 
CyC\in 82 AL080 1 46 3 .327 Repressed 
Cell Cyele cdc25A M81933 2.478 Repressed 
Associated molecule with the 
SH3 domain of ST AM AF052 135 2 . 1 99 Repressed 
(AMSH) 
DNA Replication DNA polymerase delta-2 U 2 1090 2.783 Repressed (POLD2) 
NF-kB, p52 X61 498 2.664 Repressed 
Transcription Transcription factor E2F-5 D82348 
3 .260 Repressed 
RNA polymerase II, 
D38251 3 . 1 7 1  Repressed polypeptide E (RNA pollI E) 
• Transcriptional up-rerulation of genes in bold lettering has been confIrmed by either QPCR or in vivo 
transcriptional assays. NA = Not Affected. 
The authenticity of changes in gene expression observed in the microarray analyses 
was verified by quantitative polymerase chain reaction (QPCR) for a representative 
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group of gene targets (Figure 24). Gene specific primers were designed to detect and 
determine relative mRNA levels in cells expressing mutant p53 compared to control 
cells. QPCR was performed using the Light Cycler (Roche) with the DNA-binding dye 
SYBR Green (Molecular Probes) that binds to the minor grooves of the DNA double 
helix. Total RNA was isolated from stably transfected H 1 299 cell lines expressing the 
mutant p53 protein (-D2 8 I G-5, -R273H- 1 4  and -R1 75H-72). The isolated RNA was 
DNAse treated and reverse transcribed using commercial kits from Invitrogen to 
generate the cDNA used in the experiment as described earlier [ 1 56]. Primers were 
designed using Oligo 5 (Molecular Biology Insights). 
Figure 24. QPCR analysis of cells expressing mutant p53 .  
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H 1299 cells expressing a transactivation deficient mutant p53-D281G 
(L22QIW23S) are deficient in up-regulating mutant p53 targets. Cells expressing 
43 
the triple mutant p53-D28 1 G  (L22Q/W23S) were also examined by QPCR. This 
transactivation deficient mutant did not retain the ability to up-regulate expression of 
mutant p53 target genes identified by the microarray expression analysis. As shown in 
Figure 25, in all the cases examined, the presence of the two additional mutations within 
the transactivation domain resulted in a significant loss of up-regulation compared to the 
transactivating counterpart. The combined data presented indicates that transactivation 
by tumor-derived p53 mutants is directly related to the mutant p53 protein's ability to 
induce gain-of-function properties in cells in which they are expressed. 
Promoters and cloned upstream sequences of a number of genes up-regulated by 
p53 mutants are transactivated in transient transcriptional assays. To determine 
whether the promoters of some of the genes whose expression was found to be up­
regulated are transactivated by mutant p53 in transient transcriptional assays, seven 
promoters or presumptive promoters of the up-regulated genes were assayed. The 
presumptive promoters for angiopoietin 1 (ANGPTl ), integrin a6 (IT AG6), cyclin B2, 
polymerase delta subunit 2 (POLD2) and E2F-5 were cloned from genomic DNA as 
described in Materials and Methods using information obtained in the NCBI database. 
Figure 25. Transactivation deficient mutant p53 fails to up-regulated genes in vivo . 
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Functions of the promoters of estrogen responsive A9 (EBAG9) [2 1 5] and asparagine 
synthetase (ASNS) [2 1 2] ,  and the presumptive promoters for ANGPT l ,  ITGA6, Cyclin 
B2, POLD2 and E2F-5 were studied using a luciferase reporter plasmid and p53 null 
human osteosarcoma Saos-2 cells [ 1 56] in the presence and absence of WT or mutant p53 
expression plasmids. The results obtained show that mutant p53 can transactivate the 
promoters tested (Figure 26). 
Figure 26. Promoter analysis of genes identified by microarray analysis. 
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Similar results were obtained with the Cyclin B2, POLD2 and E2F-5 promoters (data 
not shown). Although there is some variation among the p53 mutants, they all have the 
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capacity to transactivate the promoters, suggesting a uniformity of function. WTp53 
repressed all the promoters tested. The transcriptional data from these promoters further 
verifies the earlier results of the microarray hybridization analysis. 
Other p53 mutants were also tested for transactivation of the ASNS promoter (Figure 
27). As can be seen in the figure, the different mutants up-regulated the ASNS promoter 
to various degrees, further suggesting that p53 mutants may induce oncogenic properties 
through a common molecular mechanism. 
Figure 27. Mutant p53 mediated transactivation of the ASNS gene. 
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Figure 28. Mutant p53-R273H increases protein level expression of ASNS. 
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Transactivation of the ASNS promoter by mutant p53 was concentration dependent 
for p53-R273H and -D28 1 G. Furthermore, adenoviral infection of H l 299 cells with an 
adenovirus expressing mutant p53-R273H at increasing multiplicities of infection (MOl) 
resulted in increased asparagine synthetase protein levels (Figure 28). 
Chromatin immunoprecipitation reveals the presence of mutant p53 on the 
ASNS and hTERT promoters. We carried out Chromatin Immunoprecipitation (ChIP) 
[2 1 6] assays to determine the presence of mutant p53 in the promoter region of the ASNS 
genes using antibodies specific for p53 or an IgG control. Cell extracts prepared from the 
mutant p53-R273H expressing H 1 299 cell line were used for immunoprecipitation as 
described in Experimental Methods. The presence of an ASNS promoter fragment in the 
immunoprecipitated DNA was detected using specific PCR primers. QPCR analysis of 
the immunoprecipitate reveals that mutant p53 localizes on the ASNS promoter (Figure 
29). The figure shows results from two independent immunoprecipitations. Each PCR 
reaction was performed in duplicate. 
Figure 29. Mutant p53 localizes on the ASNS promoter. 
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c. Chapter Summary. 
Gain-of-function phenotypes are most likely the result of transcriptional changes 
induced by the expression of mutant pS3 in cells. It had been shown earlier that 
transactivation deficient forms of mutant pS3 did not increase the tumorigenic potential 
of 1 0(3) when injected into nude mice [ 1 33 ,  I S6] . Moreover, inhibition of mutant pS3 
through RNA interference also decreased gain-of-function phenotypes [ 1 48] .  Therefore, 
in order to identify the genes responsible for the observed phenotypes, global gene 
expression analyses were carried out using pS3-null H I 299 cells stably transfected to 
express mutant pS3 (-R 1 7SH, -R273H and -D28 1 G). 
A thorough and stringent analysis revealed I SO genes up-regulated by the expression 
of mutant pS3 .  These genes were inhibited or unaffected in the presence of WTpS3 .  Up­
regulation of a number of these genes was confirmed by QPCR and transient 
transcriptional promoter analyses; expression of the transactivation deficient mutant pS3-
D28 1 G  (L22QIW23S) did not result in up-regulation of the tested genes, further 
supporting the idea that transactivation of genes is directly related to gain-of-function 
phenotypes. Using the ASNS gene promoter as a model, it was shown that 
transactivation by mutant pS3-R273H and -D28 1 G was concentration dependent and that 
the increased transcription did indeed result in increased ASNS protein levels. Finally, 
using chromatin immunoprecipitations, localization of the mutant pS3-R273H protein 
was detected on the ASNS promoter. 
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M. Discussion. 
Since the C-terminal region of wild-type p53 harbors the oligomerization domain, and 
oligomerization is necessary for the biological functions of wild-type p53 [6, 23, 1 80, 
1 9 1 , 2 1 7] ,  it was hypothesized that the C-terminal sequences for mutant p53 would be 
required for oligomerization, and the oligomerization may be critical for gain-of-function 
[ 1 34]. This hypothesis was tested using several different approaches. 
First, the tetramerization domain of p53-D28 1 G was replaced with either a coiled-coil 
dimerization domain from the yeast GCN4 protein (p53-D281  G 343cc) or a modified 
coiled-coil domain that can act as a tetramerization motif (p53-D281  G TZN4). The 
transcriptional data generated with these heterologous constructs showed that mutant p53 
required the C-terminally located oligomerization and non-sequence-specific nucleic 
acid-binding domain for its transactivation properties (Figure 5). This requirement was 
sequence-specific and not met by merely allowing the protein to oligomerize (Figure 6). 
Similar experiments were carried out using WTp53 (data not shown). However, in the 
context of WTp53, replacement of the tetramerization domain of WTp53 by the 
dimerization domain (WTp53 343cc) could effectively sustain transactivation and growth 
suppression functions of WTp53 [ 1 76, 1 78-1 80, 2 1 8], data not shown] .  
Interestingly, the replacement of WTp53 ' s  tetramerization domain by a derivative of 
the coiled-coil structure resulting in a tetramerization domain could not induce 
transcription from the human p2 1 promoter as well as p53 343cc (data not shown). The 
reason for this apparent discrepancy is unknown, but could be related to the DNA 
concentrations used in the different transfections [23] .  Also, the wild-type p53 
derivatives inhibited the CMV immediate-early promoter significantly; the extent of 
inhibition is comparable to that mediated by wild-type p53 (data not shown). Thus, the 
functions of wild-type p53 were preserved using the various oligomerization domain 
derivatives as was shown earlier [ 1 76, 1 78-1 80, 2 1 8] .  
As a second approach, a N-termina1 deletion mutant o f  p53 was used. This deletion 
mutant retained the oligomerization domain but dispenses off the transactivation domain 
and a large portion of the sequence-specific DNA-binding domain, inactivating the 
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transactivation and DNA-binding activities of wild-type p53 [23] .  Co-transfection 
followed by irnmunoprecipitation analysis showed that p53 del. 1 -293 forms hetero­
oligomeric complexes with p53-D28 1 G  (Figure 9). This interaction also inhibited mutant 
p53-D2 8 1 G-mediated transactivation of the EGFR and MDRI promoters, suggesting that 
hetero-oligomerization inactivates transcriptional functions of mutant p53 (Figures 7 and 
8). Interestingly, this decreased transactivation was only partial in stably transfected 
murine 1 0(3) cells and although 1 0(3) cells stably transfected with p53-D28 1 G  express 5 
to 6-fold more PCNA and NF-KB2 mRNA compared to the cells transfected with vector 
alone, co-expression of p53 del. 1 -293 reduced this transactivation only partially (Figure 
1 0). The data, therefore, support the idea that proper oligomeric forms of mutant p53 are 
required for its transactivation function. 
Since replacement of the oligomerization domain of p53-D281  G inhibited the 
transactivation ability of the mutant protein while having little of no effect in the context 
of WTp53,  the data strongly suggest that the C-terminal region of WTp53 mainly 
functions in oligomerization whereas in the context of mutant p53 it seems to perform 
additional functions. Thus, there is a clear distinction in the requirement of the C­
terminal domain for wild-type and mutant p53-mediated transcriptional functions. A 
number of possible explanations for this requirement can be offered: 1 )  WTp53 has a 
nucleic acid binding activity associated with its C-terminal region [9, 1 79] . It is possible 
that under appropriate conditions mutant p53 utilizes this activity to interact with 
promoter elements and other factors to drive transcription from a promoter. 2) A number 
of post-translational modifications, such as phosphorylation and acetylation have been 
reported to occur in specific sites located near the C-terminus of WTp53 [34, 35,  2 1 9] ;  
perhaps mutant p53 requires these modifications for its transactivation function. 3)  
Finally, the C-terminal region could be a site for protein-protein interactions [i.e., c-abl, 
[220]] needed for mutant p53-mediated transactivation. The over-expression of p53 del. 
1 -293 would compete for such modifications or functions with the intact protein resulting 
in inhibition or decrease in transactivation. Analyses involving more specific mutations 
near the C-terminus along with functional assays are required before a comprehensive 
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idea and solid conclusions about the function of the C-tenninus in mutant p53-mediated 
transactivation can be made. 
Since co-expression of p53 del. 1 -293 with p53-D28 1 G inhibited transactivation, it 
was expected that this interaction would also inhibit gain-of-function properties. Results 
shown in Tables I and 2, however, indicate that this is not the case. Co-expression of 
p53 del. 1 -293 did not inhibit colony fonnation and tumorigenicity induced by mutant 
p53-D28I  G. Co-immunoprecipitation experiments showed that indeed these proteins 
interact with each other in vivo (Figure I I ). Thus, hetero-oligomerization between p53-
D28 1 G and p53 del. 1 -293 may not inhibit the growth enhancing properties of the full­
length p53-D28 1 G, although it does inhibit its transactivation property. This obserVation 
seems to go against the notion that transactivation by tumor-derived p53 mutants may be 
responsible for the gain-of-function. 
It is necessary then to point out that before reaching such a conclusion, it must be first 
shown that all the mutant p53 protein molecules are complexed with p53 del. 1 -293, and 
that every complex in every stably transfected cell contains at least one molecule of p53 
del. 1 -293 capable of inhibiting transactivation by the tetrameric complex. Although p53 
del. 1 -293 and p53-D28 1 G can fonn hetero-oligomeric complexes in 1 0(3) cells, it is 
possible that any free mutant p53 tetramer could induce the gain-of-function properties 
observed. It is also possible that because of extended number of passages the cells have 
gone through, the 1 0(3) cells expressing p53-D28 1 G became spontaneously transfonned 
independent of the involvement of mutant p53-D28 1 G; in such a case inhibiting mutant 
p53 transactivation activity would not decrease its oncogenic potential. Murine 1 0(3) 
cells indeed have a tendency to spontaneously transfonn when cultured for prolonged 
periods of time (Deb S., unpublished data). However, the conclusions that can be drawn 
from this portion of the research are that mutant p53 requires both its C-tenninal 
sequences and proper oligomerization for transactivation and gain-of-function properties. 
Expression of gain-of-function p53 mutants has also been shown to increase the 
growth rate of cells, decrease sensitivity to chemotherapeutic drugs, interfere with p53-
independent apoptosis, and induce centrosome abnonnalities in cells among other 
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properties [85, 1 24, 1 28, 1 42, 22 1 ]. Gualberto et at. [ 1 23] reported that some p53 
mutants confer a dominant gain-of-function phenotype that disrupts the spindle 
checkpoint control. They have also shown that this property did not require the 
transactivation function of mutant p53. Thus, it is possible that some gain-of-function 
properties are achievable eyen in the absence of the transactivation function of mutant 
p53 and may be solely due to protein-protein interactions. 
This makes it necessary to identify which gain-of-function properties are dependent 
on transactivation and which involve other mechanisms such as protein-protein 
interactions. A study of various p53 mutants available in this laboratory using a colony 
formation assay, revealed that the p53 mutants vary in their ability to induce a growth 
advantage suggesting that these mutants have a tumorigenic potential (Figure 1 2). 
Transcriptional reporter assays and EMSA analyses also showed that these mutants did 
not bind the WTp53 DNA binding consensus site and were unable to properly 
transactivate the human p2 1 and MDM2 promoters (Figures 1 3  and 1 4), showing that the 
mutants lack WTp53 activity. 
Using p53-RI75H, -R273H and -D281 G  as models, the data generated show that 
expression of all three of these p53 mutants can induce increased growth rates in H 1 299 
and 1 0(3) cells, decreased chemosensitivity in H 1 299 and 2 1 PT cells, and increased soft 
agar plating efficiency in Saos-2 cells (Figures 1 7, 1 9-2 1 and data not shown). In all 
three of the phenotypes studied, expression of a transactivation deficient mutant p53 
decreased or nullified the observed phenotypes. Interestingly, in Saos-2 cells, expression 
of this transactivation deficient form of mutant p53 did not completely nullify the ability 
of the cells to plate in soft agar, suggesting that transactivation is not the only factor 
involved in mediating this phenotype. This further supports previously reported data that 
certain mutant p53 gain-of-function phenotypes can be achieved independent of 
transactivation [ 1 70- 1 75]. 
Expression of mutant p53 remained directly related to the observed growth rate in 
H 1 299 cells (Figure 1 8). Inhibition of mutant p53 expression through RNA interference 
decreased the growth rate of cells to a rate comparable to that of control cells. Thus, the 
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data generated not only suggest that expression of mutant p53 was responsible for the 
phenotype, but that continuous expression of the mutant protein is necessary to maintain 
the gain-of-function phenotype observed in these cells. It was also observed that 
decreasing the mutant p53 protein levels also decreased protein levels of c-myc, 
suggesting a possible role for this protein in mutant p53-mediated enhanced growth in 
H 1 299 cells. Further experiments using this approach could be used to determine the 
exact role of mutant p53 expression in other gain-of-function phenotypes. 
In order to understand the mechanism behind the phenotypes observed In cells 
expressing mutant p53, gene expression analyses were performed to study the 
transcriptional changes that occur in cells when mutant p53 is expressed in them. Using 
microarray hybridization analyses, a group of genes was identified as regulated by the 
p53 mutants in the absence of WT. QPCR data (Figure 24) suggests that our microarray 
hybridization analysis is reliable. Some of the identified genes were found to be involved 
in cell growth, survival, adhesion and angiogenesis (Table 3). The finding that all three 
p53 mutants transactivate a common set of genes (Figure 23) in the absence of WTp53 is 
unique and provides highly significant information toward understanding mutant p53-
induced gain-of-function suggesting the existence of a common pathway utilized by p53 
mutants to aid in oncogenesis. Of the genes identified in our microarray, MCL ! ,  
EBAG9, ANGPT l ,  ITGA6, NF-KB2 and E2F-5 have been reported as up-regulated in 
various cancer types and established cell lines [205, 222-226]. Since information is not 
available in the literature, it remains to be seen whether these genes are also up-regulated 
in the natural context of the p53 mutation, i.e. in human cancers carrying a p53 mutation. 
It is important to point out that some of the genes identified in these analyses function as 
transcription factors (i.e. E2F-5 and NF-KB2), which suggests the possibility that some of 
the genes modulated by p53 may be modulated through these transcription factors. 
Further analyses will be necessary in order to sort out the array of genes modulated by 
mutant p53 into primary and secondary targets. Nevertheless, it is very likely that the 
genes modulated by mutant p53 identified here may play a role in the various gain-of­
function phenotypes that have been attributed to mutant p53 in the literature. For 
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example, the transcription factor NF-KB2 has been implicated in cell survival and 
chemoresistance, presenting a role for NF-kB2 [208, 209]. It is then possible that this 
factor is somehow involved in chemoresistance brought about by the expression of 
mutant p53 in cells (Appendix A). 
Although the exact molecular mechanism behind the gain-of-function properties of 
p53 mutants is yet to be completely clarified, transactivation of growth promoting genes 
remains a strong candidate. Another possibility that has been proposed for the observed 
gain-of-function properties is the neutralization of p73 and p63, two p53 family members 
[227-229] . Both p73 and p63 share significant sequence similarity with p53, and are able 
to transactivate promoters containing a WTp53 consensus site in their promoter region, 
such as p2 1 /WAF I and MDM2. As with WTp53, over-expression of p73 or p63 can 
result in apoptosis and cell cycle arrest [230] . Although there is sequence similarity 
between the oligomerization domains of the three proteins, WTp53 does not hetero­
oligomerize with p73 and p63 [23 1 ] . More recent reports, on the other hand, suggest that 
p53 mutants can interact with p73 and p63 and that these interactions occur via the DNA­
binding domain (amino acids 1 00-293) of the mutant p53 protein [232-234]. This 
functionally inactivates p73 (and p63) and there is evidence to suggest that this 
interaction is responsible for the decreased sensitivity to chemotherapeutic drugs that is 
observed in cells over-expressing mutant p53 [232, 233, 235].  However, data presented 
in the literature also suggest that transactivation by mutant p53 is directly related to its 
gain-of-function properties. The transactivation deficient mutant p53-D28 1 G 
(L22QIW23S) contains the same amino acid mutation within the DNA-binding domain 
as its transactivating counterpart (p53-D281  G). This mutant then should be able to 
interact with p73 and p63 and its expression in cells should result in decreased sensitivity 
to chemotherapeutic drugs. This is not the case in the H 1 299 cell culture model 
presented above. Therefore, it is possible that this phenotype may require a combination 
of transcriptional activation of certain genes as well as protein-protein interaction with 
p73, p63 and perhaps other proteins. Preliminary studies performed in the laboratory 
suggest that although p73 is present in H l 299 cells, its interaction with mutant p53 is 
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minimal [ [236] and data not shown]. Additionally, this transactivation deficient mutant 
failed to promote tumorigenicity suggesting further complexities to mutant p53 gain-of­
function [ 1 33] .  
In general, single amino acid changes have an effect in both the transactivation and 
transrepression activities of p53 (Figures 1 4  and 1 5). This is likely due to the presence of 
mutations within the DNA-binding domain [234]. Thus, a decreased ability to bind DNA 
would result in a decrease in the transactivation and repression activities of p53 . This 
does not explain however, the ability of certain p53 mutants to transactivate promoters of 
genes (i.e. peNA, IL-6, BFGF, IGF-I, and others) [reviewed in [ 1 1 9, 1 53 , 1 90, 202]] .  It 
is known that mutant · p53-mediated transactivation does not require WTp53 DNA­
binding sites, showing that the mechanism of transactivation by mutant p53 is distinct 
from that of the WTp53 protein [ 1 1 9, 1 34, 1 55] .  
Three possible molecular explanations exist for mutant p53-mediated transactivation: 
1 )  It may be that p53 mutants differ in their ability to recognize and bind responsive 
elements, although there is no strong evidence so far for any mutant p53 consensus 
sequence in the literature. In this case, mutant p53 proteins may possess a DNA binding 
ability altogether distinct from the WT protein. Analyses of mutant p53 DNA binding 
has revealed that the mutant p53 protein can physically associate with certain responsive 
promoters indicating that mutant p53 proteins are targeted to DNA in a specific manner 
[ 1 52, 237]. Intriguingly, sequence analysis of mutant p53 responsive promoters has yet 
to show any sequence homology nor describe a mutant p53 specific response element. 
The question still remains, if mutant p53 can associate with DNA, then how is this 
occurring? It appears that the interaction of mutant p53 with DNA is determined by the 
structure of DNA and not by sequence specific motifs [238, 239] . This possibility arises 
from observations that mutant p53, but not WTp53,  binds with high affinity to Matrix 
Attachment Regions (MAR) elements. MAR elements are polymorphic, have no known 
consensus sequence and are distributed throughout the genome. In vitro binding of 
mutant p53 to MAR elements is largely dependent on the length of the DNA and not the 
sequence [240] . This is further supported by findings that mutant p53 proteins bind with 
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high affinity to  DNA sequences with a propensity to undergo structural transitions [24 1 ,  
242]. The finding that transactivation of some promoters by mutant p53 requires both the 
DNA binding and C-terminal domains seems to support this idea [ 1 34, 1 54, 1 56, 243] .  
DNA structure-dependent recognition would explain the lack o f  sequence similarity 
between the various mutant p53 responsive promoters. Searching for structural 
similarities in the DNA rather than sequence motifs may be a more meaningful approach 
to understanding mutant p53-mediated transactivation. 
2) A second possibility is that mutant p53-mediated induction of mRNA, as judged by 
microarray or QPCR analysis, is the result of stabilization of RNA by a post­
transcriptional mechanism, although no direct evidence exists for this mechanism either. 
The results of the promoter analyses suggest that RNA stabilization is not a mechanism 
of mutant p53 mediated gene up-regulation, at least for the target genes identified here. 
3) A third explanation for mutant p53-mediated transactivation is the possibility that 
mutant p53 targets promoters regulated by other transcription factors. Mutant p53 has 
been shown to interact with other sequence specific transcription and nuclear factors such 
as Spl ,  ATF/CREB or NF-KB [244-246]. Spl can interact with both WTp53 and 
mutant p53 [247, 248]. While the interaction between WTp53 and Spl may be dynamic, 
mutant p53 may become tethered to Sp 1 resulting in the up-regulation of genes. As such, 
differences in levels of transcription can be accounted for by the identity of the 
transcription factors involved, or by the relative affinity of the mutant p53 for the 
transcription factor. This model of transactivation is presented in Figure 30. 
Since different promoters behave differently towards p53 (WT or mutant), it is 
possible that the arrangement of other transcription factors present on a promoter 
influence the effects of p53 on the overall transcription of that promoter. While WTp53 
inhibits Spl -mediated transcription by interfering with DNA binding of Spl ,  mutant p53 
seems to enhance the activation potential of Sp 1 [249] suggesting that stereo-specific 
complexes containing either WT or mutant p53 are functionally different. On the other 
hand, the regulation of WT and mutant p53 of MDRI involves different promoter regions 
[250]. Taken together, proximity, arrangement and/or physical contact of the mutant p53 
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with transcriptional factor(s) or complex(es) may determine the outcome of the 
interaction. 
Figure 30. Proposed model of transactivation. 
WT p53 
(.;o-reor-ess,or (mSin3AIHDAC) Mutant p53 
R NApo1 1 i  complex 
NF-kB2 NF-kB2 
-"-I"� � - Repression � - Activation 
Sp1 or other Sp1 or other 
transcription factor transcription factor 
In fact, a computer-based sequence analysis of genes listed in Table 3 reveals that 
several of the genes identified here contain Sp 1 sites reportedly involved in the 
transcriptional regulation of the gene (Figure 30). Mutant p53 transactivation may indeed 
function through these sites. Using an algorithm designed by Hoh et al. [25 1 ]  to find 
presumptive p53-binding sites on the upstream sequences (approximately 2000bp up­
stream from the 5'end of the mRNA) of genes listed in Table 1 it was observed that only 
in a few cases there were reasonable sites that may bind WTp53 (data not shown). These 
sites may play a role in WTp53-transcriptional repression of these promoters, a prediction 
that remains to be tested in the future. In other cases WTp53 must be repressing by 
utilizing protein-protein interactions [252, 253] .  Whether mutant p53 utilizes any of the 
WTp53 binding sites or not is an open question, although perhaps unlikely. 
The observations reported here may help formulate the role of mutant p53 in 
oncogenesis and attempts to explain why tumors expressing mutant p53 have a poorer 
prognosis. In a normal cell both the alleles of p53 are WT and p53 has full potency as a 
"protector" against stress situations such as DNA damage principally acting as a 
transcriptional activator. Because of a mutation in one of the alleles affecting the coding 
sequence of p53, a faulty mutant protein with one amino acid substitution is produced. 
Mutant p53 becomes stabilized weakening the transcriptional function of the WT protein. 
This may eventually lead to the loss of the remaining WTp53 aBele, a question that has 
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yet to be answered in the literature. This loss of heterozygosity has been reported in 
many human cancers expressing mutant p53 [6, 20-22, 79-84]. The mutant protein then 
begins working as a potential oncogenic agent transcriptionally activating growth 
promoting, angiogenic and invasive genes leading to aggressive oncogenic phenotypes 
observed in these cells. 
Figure 31. Presumptive promoters of ASNS, E2F-5, EBAG9 and CDC25A. 
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If one considers transcriptional regulation by WTp53 to be complex, then 
transcriptional regulation by mutant p53 appears to be even more complex. This 
complexity seems to arise from the fact that several rather distinct mechanisms appear to 
play a role in mutant p53-mediated regulation of transcription, resulting in the altered 
gene expression. This would explain the cell type specific gene expression changes 
associated with mutant p53 expression and the apparent difficulties in deciphering the 
mechanisms underlying mutant p53 oncogenicity and gain-of-function properties 
(Appendix B). This makes it important to identify transcriptional targets common to 
multiple p53 mutants. Definition of this pathway and the molecular mechanisms 
dictating it will provide strong candidates for cancer therapy development. 
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N. Figure and Table Legends. 
Figure 1. Structure of p53. Graphical representation of the various identified 
domains with the p53 protein. 
Figure 2. Functions of p53. Cellular damage results in the stabilization of p53 as a 
result of phosphorylation and acetylation. The p53 protein can then act as a transcription 
factor inducing up-regulation and down-regulation of various genes or as a structural 
component of protein complexes. Cells are halted at various checkpoints during the cell 
cycle or targeted for apoptosis. 
Figure 3. Differences between mutant and WTp53. Transcriptional activation by 
WTp53 leads to modulation of genes involved in tumor suppression. This is largely 
dependent on the ability of WTp53 to bind to its consensus sequence. Mutant p53 
expression, on the other hand, can lead to modulation of genes involved in tumor 
progression even in the absence of WTp53 (gain-of-function) [254]. 
Figure 4. Schematic representation of p53-D281G oligomerization derivatives. 
Schematic representation of p53-D28 1 G derivatives used in the domain exchange 
experiments. The tetramerization domain of p53 amino acid 320-360 is shown by a black 
box. p53-D28 1 G  TZ334NR has sequences from amino acids 334 to 393 replaced by a 
modified coiled-coil structural domain (green box), p53-D28 1 G TZ334NRl352 has the 
sequences 352-393 inserted after amino acid 352 following the TZ moiety, p53-D281  G 
343cc has sequences from amino acids 344 to 393 replaced by the coiled-coil structural 
domain (red box) coding for a dimerization motif from the yeast GCN4 protein. 
Figure 5. Replacement of the tetramerization domain of mutant p53 has a 
drastic effect on mutant p53-mediated transactivation. Saos-2 cells were co­
transfected with EGFR.Luc (200ng) and the expression plasmid for tumor-derived mutant 
p53-D28I G, one of its derivatives or empty vector (800ng) in a 24-well plate using 
Lipofectarnine 2000. Cell lysates were prepared 48hrs after transfection, and luciferase 
activity measured. Western blot analysis from a representative transfection showed equal 
protein expression (right inset). 
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Figure 6. Replacement of the tetramerization domain of mutant p53 preserves 
tetramerization of the protein. In vitro translated p53-D281  G and its derivatives (p53-
D28 1 G  TZ334NR, p53-D28 1 G  TZ334NR1352 and p53-D28 1 G  del. 393-327) were 
incubated with the indicated concentrations of glutaraldehyde [23]. Samples were 
separated on a gradient (4-20%) SDS-PAGE after cross-linking. The gel was dried and 
autoradiographed. Positions of presumptive monomers, dimers, trimers and tetramers of 
p53 derivatives are indicated. 
Figure 7. Transactivation of the EGFR promoter by tumor-derived mutant p53-
D281G is inhibited by co-expression of p53 del. 1 -293. Saos-2 cells were plated at 
. equal densities in 24-well plates and transfected 24hrs later. Each well was transfected 
with l 70ng of EGFR.Luc, 1 70ng of pCMVBam p53-D281  G (or vector alone) and 5 l Ong 
of pCMVBam p53 del. 1 -293 (or vector alone). Forty-eight hours after transfection, cell 
extracts were prepared and luciferase activity measured. Western blot analysis was 
carried out with equal amounts of protein from a representative transfection to evaluate 
protein expression (right inset). 
Figure 8. Transactivation of the MDR1 promoter by tumor-derived mutant p53-
D281 G  is inhibited by co-expression of p53 del. 1-293. Saos-2 cells were plated at 
equal densities in 1 0cm plates and transfected the following day using the calcium 
phosphate precipitation method. Cells were transfected with 2.5J.lg of MDR l .CAT, 
2.5J.lg of pCMVBam p53-D28 1 G  (or vector alone) and 7.5J.lg of pCMVBam p53 del. 1 -
293 (or vector alone). After transfection, cells were treated as described in Experimental 
Methods and CAT assays performed. Western blot analysis was carried out with equal 
amounts of protein from a representative transfection to evaluate protein expression (right 
inset). 
Figure 9. p53 del. 1 -293 co-immunoprecipitates with p53-D281G. Saos-2 cells 
were transfected in 1 0cm plates with 3 .2J.lg of the expression plasmid for p53-D28 1 G  (or 
expression vector alone) and 9.6J.lg of an expression plasmid for p53 del. 1 -293 (or 
expression vector alone). Twenty-four hours after transfection, cellular proteins were 
labeled in vivo by 35S-methionine. Extracts were then prepared and immunoprecipitated 
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with monoclonal antibodies as depicted in the figure. The immunoprecipitates were 
resolved in a 1 5% SDS-polyacrylamide gel followed by autoradiography. The left panel 
shows the binding sites for monoclonal antibodies PAb421 and DO l on p53-D28 1 G. 
Figure 10. Co-expression of p53 del. 1-293 inhibits transactivation by p53-
D281 G. Total RNA was prepared from 1 0(3) cells stably transfected with vector alone, 
p53-D28 1 G, p53 del. 1 -293, or p53-D28 1 G  and p53 del. 1 -293. Quantitative real time 
PCR was perfonned to detennine the relative amounts of mRNA for NF-KB2 and PCNA 
genes. Graphs show the relative levels of PCNA and NF-KB2 mRNAs (nonnalized to 
GAPDH levels within the cells) in different stable transfectants of 1 0(3) cells. 
Table 1. Colony formation in 10(3) cells stably transfected with vector or p53-
D281 G. 1 0(3) cells stably transfected with the vector pCMVBam Neo [255] or stably 
expressing p53-D28 1 G  [ 1 34] were transfected with I J.lg of pHyg and 5J.lg of the indicated 
p53 or p73 expression plasmid [23, 1 88, 1 97] . Transfections were carried out by the 
calcium phosphate precipitation method [ 1 34] . After 48hrs, cells were sub-cultured 1 :4 
and allowed to fonn colonies in the presence of hygromycin (200 J.lg/ml). The media was 
changed every 2-3 days. After 3 weeks, cells were fixed with methanol and stained by 
methelyne blue. 
Table 2. Tumorigenicity of 10(3) cells expressing p53 derivatives. The 
tumorigenic potential of 1 0(3) cells expressing p53 derivatives was tested using nude 
mice. Cells (5 x 1 06 per site) were subcutaneously injected into flanks of athymic nude 
mice (National Cancer Institute) and tumor development was monitored as described 
[ 1 1 ] ; [ 1 34]. 
Figure 1 1 . Hetero-oligomers are produced between p53-D281 G  and p53 del. 1-
293 in 10(3) cells stably expressing the two proteins. Cell extracts from 1 0(3) cells 
expressing p53 del. 1 -293 alone or expressing p53-D2 8 1 G  and p53 del. 1 -293 were 
prepared and immunoprecipitation reactions perfonned with the antibody DO l 
(Oncogene, Ab-6). The immunoprecipitates were then separated by SDS-PAGE 
followed by western blot analysis. The blot was developed with PAb42 1 .  Antibody DO l 
was run as a control to depict the positions of light and heavy chains of IgG. Positions of 
6 1  
molecular weight markers are shown. The figure shows results from duplicate 
irnmnoprecipitations. 
Figure 12. Expression of tumor-derived mutant p53 increases the formation of 
neomycin resistant colonies. 1 0(3) cells were plated at equal densities ( 1 06 cells per 
plate) 24 hrs prior to transfection. Cells were transfected with pCMV-Bam Neo and 
WTp53 or mutant p53 (or vector alone) using the calcium phosphate precipitation 
method. The cells were subcultured 1 :4 48 hrs after transfection and Neomycin (G4 1 8) 
was added to start the selection process. After 3 weeks, cells were fixed with methanol 
and stained; colonies containing more than thirty cells were counted. The final counts 
were as follows: ( 1 )  pCMV-Bam: 4 1 ,  3 1 ,  42 Avg. 38  (2) pCMV-Bain WTp53 :  24, 25, 24 
Avg. 24.3 ,  (3) pCMV-Bam p53-V I 43A: 55, 48, 65 Avg. 56, (4) pCMV-Bam p53-L l 57F: 
39, 34, 45 Avg. 39.3, (5) pCMV-Bam p53- 1 63C:  64, 63, 73 Avg. 66.7, (6) pCMV-Bam 
p53-RI 75H: 88, 77, 95 Avg. 86.7, (7) pCMV-Bam p53- 1 79Y: 42, 44, 5 1  Avg. 43, (8) 
pCMV-Bam p53- 1 94R 60, 58, 5 1  Avg. 56.3, (9) pCMV-Bam p53-R273H:  1 1 2, 1 1 0, 1 06 
Avg. 1 09.3, ( 1 0) pCMV-Bam p53-D28 1 G: 1 24, 1 29, 1 3 7  Avg. 1 30, and ( 1 1 )  pCMV­
Bam p53-R282W: 72, 60, 68 Avg. 66.7. The figure shows the number of average 
colonies formed. 
Figure 13. DNA binding of WT and tumor-derived p53 mutants. Saos-2 cells 
were transfected with 1 0J.lg of the expression plasmid containing WT or mutant p53, 
whole cell extracts were prepared as described in Experimental Methods and DNA 
binding reactions carried out as described in the text. The probe (P2 1 WT) used contained 
the p53 binding sequence found in the p2 1 promoter (distal site). Lanes 1 -5 were 
incubated with purified p53 protein ( 1 00 ng), lanes 6-23 were incubated with an extract 
obtained from whole cell Iysates containing approximately 1 0J.lg of total protein. WTp53 
can bind the probe sequence containing the p53-binding sites (Lanes 2 - 12). A cold 
competitor (P2 1 WT, lanes 2, 3, 8, 9) and a non-specific competitor (P2 1 MT, lanes 4, 5 ,  
1 0, 1 1 ) were also used. A p53-specific antibody (Ab-6, Oncogene) was used to  generate 
a supershift of the p53-bound probe (lane 1 2). Tumor-derived p53 mutants were 
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analyzed for DNA binding to the same probe set (lanes 1 3-23). No binding was detected 
for these tumor-derived p53 mutants 
Figure 14. Transcriptional activation of p53-inducible promoters by mutant 
p53. Human osteosarcoma Saos-2 cells were transfected using Lipofectamine 2000 
(Invitrogen) with p2 1 .Luc or MDM2.Luc (200ng), and the expression vector containing 
the WT or mutant p53 cDNA (25ng with p2 1 . 1uc, 1 00ng with MDM2.Luc). Cells were 
grown for forty-eight hours, cell lysates prepared, and luciferase activity measured. The 
vector reading was set to 1 00 and the relative luciferase activity in the remaining extracts 
calculated with respect to the vector. Western blot analysis was performed to confirm 
equal expression of the protein after transfection in a representative experiment using the 
specific antibody P Ab 1 80 1 (data not shown). 
Figure 15. Transcriptional activation of p53-repressed promoters by mutant 
p53. Human osteosarcoma Saos-2 cells were transfected using Lipofectamine 2000 
(Invitrogen) with SV40.Luc (200ng), and the expression vector containing the WT or 
mutant p53 cDNA (800ng). Cells were grown for forty-eight hours, cell lysates prepared, 
and luciferase activity was measured. The vector reading was set to 1 00 and the relative 
luciferase activity in the remaining extracts calculated with respect to the vector. 
Western blot analysis was performed to confirm equal expression of the protein after 
transfection in a representative experiment using the specific antibody PAb 1 80 1 (data not 
shown). 
Figure 16. Expression of mutant p53 in 8 1299 cells. Human p53-null H 1 299 cells 
were transfected using Lipofectamine 2000 (Invitrogen) with expression plasmids for 
mutant p53 (or vector alone) as indicated. Forty-eight hours after transfection, cells were 
sub-cultured 1 :3 and neomycin added at a concentration of 400 Ilg/ml to begin the 
selection process. After 3-4 weeks of selection, individual colonies were cultured 
independently and checked for p53 expression using the antibody Pab 1 80 1 .  Clones with 
similar expression levels were selected for microarray hybridization analyses. Asterisks 
indicate cell lines used for microarray hybridizations analyses. 
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Figure 1 7. Mutant p53 expression results in enhance growth rates in 91299 
cells. Cells were seeded at a density of I x 1 05 cells per 60mm plate. Five plates of each 
cell line were plated initially (Day 0). One plate of each was trypsinized, and cells 
suspended in I ml of serum containing media. Cells were counted and the total number of 
cells calculated and plotted for each day. Standard deviations result from three 
independent experiments run simultaneously. Mutant-pS3 expressing cell lines were 
compared to the control cell line HC-S . Only days 2-S are shown. 
Figure 18. The increased growth rate phenotype is dependent on mutant p53 
expression. H I 299 cells expressing pS3-RI 7SH or vector alone (HC-S) were transfected 
using Lipofectamine 2000 with siRNA directed against pS3 ('pS3 ' )  or a non-specific 
control sequence ( 'C') .  Cells were transfected a second time with the same siRNAs 
24hrs later. A. Mutant pS3 protein levels were detected 2 to 7 days after the first 
transfection using the antibody PAb 1 80 I in a parallel experiment; �-actin was used as a 
loading control . B. Transfected cells were plated at equal density 48hrs after the first 
transfection (Day 2) in 96-well plates. Cell viability was measured using an MTS assay 
kit (Promega) for the following five days. Viability of cell lines transfected with control 
siRNA (top) or siRNA directed against pS3 (bottom). Cell viability is expressed as a 
percentage of HC-S control cells on the indicated day. C. In a separate experiment, 
H I 299 cells transfected with siRNA against pS3 were harvested 48hrs after transfection 
and equal amounts of protein separated by SDS-PAGE. C-myc and pS3 were detected 
using the specific antibodies (Oncogene, Ab-6 and Ab- I ). 
Figure 19. Expression of mutant p53 in 9 1299 results in decreased sensitivity to 
etoposide. Cells were plated at S x 1 04 cells/plate and treated with 61lM etoposide (final 
concentration) for 48hrs. After treatment, cells were washed with HBSS and the 
surviving cells allowed to recuperate for three weeks with periodic changes of media. 
The colonies formed were fixed with methanol, stained with methylene blue and counted. 
The data shown is representative of three independent experiments run simultaneously; 
colony numbers were adjusted to account for plating differences based on control plates. 
Control plates were plated at one-tenth the density and treated with an equal amount of 
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vehicle control (OMSO) for 48hrs with less than 1 0% plating difference (data not 
shown). Clones H l 299 cells expressing mutant p53-R I 75H, -R273H, -028 1 G, p53-
028 1 G  (L22Q/W23S) or vector alone were used. 
Figure 20. Pools of mutant p53-expressing 81299 cells recapitulate results 
obtained with individual clones. Cells were plated at 5 x 104 cells/plate and treated 
with 61lM etoposide (final concentration) for 48hrs. After treatment, cells were washed 
with HBSS and the surviving cells allowed to recuperate for three weeks with periodic 
changes of media. The colonies formed were fixed with methanol, stained with 
methylene blue and counted. The data shown is representative of three independent 
experiments run simultaneously; colony numbers were adjusted to account for plating 
differences based on control plates. Control plates were plated at one-tenth the cell 
density and treated with an equal amount of vehicle control (OMSO) for 48hrs with less 
than 1 0% plating difference (data not shown). Pools of H 1 299 cells expressing p53-
R 1 75H, p53-R1 75 H  (L22Q/W23S), -R273H, -028 1 G, or vector alone were used. 
Figure 2 1 .  Mutant p53-expressing Saos-2 cells exhibit increased plating in soft 
agar. Saos-2 cells expressing mutant p53-028 1 G, the transactivation deficient p53-
028 1 G (L22Q/W23S) or vector alone were plated at a density of 3000 cells/well in 6-
well plates over a .5% agar plug. Cells were grown in .25% agar medium for 4-5 weeks 
with periodic additions of media. Approximately I % of vector-transfected cells formed 
colonies, whereas mutant p53-0281  G displayed an increased ability (5- 1 0%) to grow in 
soft agar. Cells expressing mutant p53-028 1 G  (L22Q/W23S) had a comparative growth 
of 2-3%. 
Figure 22. Scatter-gram analysis of S-scores generated. Scatter plot analyses of 
the S-scores obtained after analysis of the microarray hybridization data. The plot 
represents two unpaired comparisons (mutant p53 expressing vs. vector control cells) 
graphed against each other. The plots show a very high degree of consistency of changes 
in gene expression between biological duplicates. The scattergrams also indicate a 
relatively large number of changes in gene expression in each of the mutant p53-
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expressing cell lines versus the control cell line. Clustering of the points around zero 
would have indicated few or no changes occurring. 
Figure 23. Expression of mutant p53 in H1299 changes the cellular 
transcriptional profile. Cluster analysis of the output gene list obtained from our SAM 
analysis of the H 1 299. Microarray hybridization analysis of cell clones expressing 
mutant p53 (-R1 75H, -R273H and -D28 1 G) derived from H1 299 cells using Affymetrix 
GeneChip TM System U95A v2 chip reveals the up-regulation of a set of 1 50 genes up­
regulated in the presence of all three p53 mutants, but identified as inhibited or 
unaffected by WTp53 (not shown). Changes in gene expression were detected in terms of 
statistical significance (S-score) of change in expression for a given gene between two 
microarrays. WTp53 hybridizations were generated from WTp53 infected cells 
compared to �-galactosidase infected samples (data not shown). The Cluster and 
TreeView programs (http://rana.lbl.govl) were used to provide graphical displays of the 
gene expression patterns [256, 257]. Gene names and accession numbers have been 
removed for ease of viewing. FDR = 0.3% 
Table 3. Microarray hybridization analysis of RNA from H 1 299 cells expressing 
mutant p53-RI 75H, -R273H and -D281G in comparison to vector transfected cells. 
Only up-regulated genes are listed on the table. Initial functional grouping of the genes 
was performed with the EASE program [258]. 
Figure 24. QPCR analysis of cells expressing mutant p53. mRNA was extracted 
from exponentially growing plates of the indicated cell lines and cDNA prepared. The 
cDNA was then analyzed by QPCR using gene-specific primers for various genes 
identified through microarray hybridization analysis. The degree of expression was 
quantitated using a relative standard curve and normalized to an internal control [Brome 
Mosaic Virus (BMV) RNA] corresponding to the cDNA batch ( 1 56].  The normalized 
mRNA level in the HC-5 control cell line was arbitrarily set to 1 and the relative fold 
difference calculated for the remaining samples. 
Figure 25. Transactivation deficient mutant p53 fails to up-regulate genes in 
vivo. mRNA was extracted from exponentially growing plates of the indicated cell lines 
66 
and cDNA prepared. The cDNA was then analyzed by QPCR using gene-specific 
primers for various genes identified through microarray hybridization analysis as up­
regulated by mutant p53 .  The degree of expression was quantitated using a relative 
standard curve and normalized to an internal control [Brome Mosaic Virus (BMV) RNA] 
corresponding to the cDNA batch [ 1 56]. The normalized mRNA level in the HC-5 
control cell line was arbitrarily set to 1 and the relative fold difference calculated for the 
remaining samples. 
Figure 26. Promoter analysis of a group of representative genes identified by 
microarray analysis. The presumptive promoters for ANGPTl and ITGA6 were cloned 
from genomic DNA using information obtained in the NCB! database (see Materials and 
Methods). The promoters of ASNS and EBAG9 were obtained from outside sources 
[2 12 ,  2 1 5] .  Promoters were studied using reporter luciferase constructs and p53 null 
human osteosarcoma Saos-2 cells as described in Experimental Methods. The vector 
reading was arbitrarily set to 1 00. 
Figure 27. Mutant p53 mediated transactivation of the ASNS gene. Human 
osteosarcoma Saos-2 cells were transfected with 200ng of ASNS.Luc and 250ng of the 
expression vector for WT or mutant p53 as indicated. Cell lysates were prepared 48hrs 
after transfection and luciferase activity was measured. The vector reading was set to 
1 00 and the relative luciferase activity in the remaining extracts calculated with respect to 
the vector. Western blot analysis was performed to confirm equal expression of the 
protein after transfection in a representative experiment using the specific antibody 
PAb 1 80 1  (data not shown). 
Figure 28. Mutant p53-R273H increases protein level expression of ASNS. Right 
panel. Saos-2 cells were transfected with 200ng of ASNS.Luc and increasing amounts of 
mutant p53 expression plasmid (p53-R273H or -D281  G) as indicated. Cell lysates were 
prepared and luciferase activity was measured 48hrs after transfection. The vector 
reading was set to 1 00. Left panel. H l 299 cells were plated at equal densities and 
infected with increasing multiplicities of infection 24 hrs later using an adenovirus 
expressing mutant p53-R273H (or �-gal as a control). Cell lysates were prepared 48hrs 
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later and western blotting performed to detect protein levels of ASNS (upper panel). 
Samples were normalized based on total protein readings. Actin was used as a loading 
control (lower panel). H 1 299 cells transiently transfected with an expression plasmid 
containing the ASNS cDNA were used as a positive control.  
Figure 29. Mutant p53 localizes on the ASNS promoter. Exponentially growing 
cells of H-273H- 1 4  cell line were crosslinked, and harvested as described in 
Experimental Methods. p53 was immunoprecipitated using the specified antibody 
(DO 1 ). Normal IgG was used in the control immunoprecipitation. The presence of the 
ASNS promoters in the immunoprecipitate was detected using QPCR specific primers. 
The graph shows the fold difference in Antibody/Input ratio of the QPCR signals 
obtained for the specified antibody in two independent immunoprecipitation experiments. 
The average fold difference for the signals and standard deviations were also calculated 
(right). 
Figure 30. Proposed model of transactivation. Left panel: Schematic 
representation of WTp53 repressed NF-KB2 promoter. WTp53 localizes on the promoter 
region by binding to other transcription factors (i.e. Sp l ,  NF-KB, etc). Repression of 
transcription occurs through the action of a co-repressor protein such as mSin3 or Histone 
deacetylase (HDAC) [259]. Right panel: We propose that mutant p53 retains the ability 
to bind some transcription factors. Therefore, it is possible for mutant p53 to localize on 
the promoter by binding to Spl or another transcription factor but is unable to repress 
transcription since it has lost the ability to bind the co-repressor. The intact 
transactivation domain of the mutant protein can then interact with the RNA polymerase 
complex, independently or through a co-activator thus increasing transcription of the 
gene. 
Figure 31 .  Presumptive promoters of ASNS, E2F-5, EBAG9 and CDC25A. The 
transcription factor binding sites were identified using a world wide web base search 
program (TFSEARCH- Transcription Binding search) found at 
http://www.cbrc.jp/researchidbITFSEARCH.html). Only those binding sites with high 
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probability (>90%) are shown. The presumptive transcription initiation site is denoted by 
a black upright bar and the A TG codon by a horizontal bar. 
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o. Experimental Methods. 
General Methods. 
Plasmids and DNA. The p53 and p73 expression plasmids contained the human p53 
and p73 cDNAs under the regulation of the CMV immediate-early promoter in the 
pCMVBam expression vector [ 1 88, 255) .  The N-terminal deletion derivative p53 del. 1 -
293 was generated in the context of the human wild-type p53 cDNA as described earlier 
[23) .  p73a and p73 p cDNAs were cloned in such a way that they have a FLAG epitope 
at the N-terminus when converted into the respective proteins [ 1 97). 
The p53 C-terminal derivatives have been described earlier [ 1 78, 1 80). The p53 
343cc had sequences from amino acids 344-393 replaced with the coiled-coil structural 
domain from the yeast GCN4 protein, while p53 TZ334NR had sequences from amino 
acids 334-393 replaced by a modified coiled-coil structure defining a tetramerization 
domain. The p53-D2 8 1  G forms of these derivatives contained the amino acid 
substitution at the position 2 8 1  from Arg to Gly; these clones were constructed by 
standard sub-cloning techniques by replacing a restriction fragment of the wild-type p53 
cDNA overlapping the sequence coding for amino acid 2 8 1  with the corresponding 
fragment from p53-D28 1 G  cDNA. All coding sequences were cloned in the pCMVBam 
vector in the correct orientation downstream of the CMV immediate-early promoter. 
The chloramphenicol acetyltransferase (CAT) plasmids utilized the Escherichia coli 
CAT gene under the transcriptional control of the MDRI [ 1 34] promoter. The luciferase 
plasmids used the firefly luciferase (Iuc) gene under the control of the human EGFR and 
p2 1 promoters [40, 1 97). The p53 mutants (p53-V I 57F, p53-Y I 63C, p53-H I 79Y, p53-
L l 94R, p53-R282W) in pCMV-Bam used in this study were generated using the Quick 
Change Site directed Mutagenesis (Stratagene) following the manufacturer's protocol. 
Sequencing was performed after mutagenesis to confirm the presence of the desired 
mutation. pCMV-Bam WTp53, p53-V I 43A, p53-RI 75H, p53-R273H, and p53-D28 1 G  
were described earlier [ 1 56] . MDM2.Luc, p2 1 .Luc, and c-myc.Luc [40, 1 97] , ASNS.Luc 
[2 1 1 , 2 1 2] and hTERT.Luc [260] have been described earlier. 
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Generation of stable cell lines expressing mutant p53. The p53-null human lung 
carcinoma cell lines H l 299 [26 1 ], human 2 1 PT [262], human Saos-2 [ 1 56] and the 
murine fibroblast 1 0(3) cell line were transfected using Lipofectamine 2000 or the 
calcium phosphate method [ 1 88] with pCMVBam Neo or pCMVBam Neo-mutant p53 
expression plasmid as indicated [255]. Control and mutant p53-expressing stable cell 
lines were generated: 1 0(3) Vector 4 [ 1 0(3)-V4], 1 0(3) p53-D28I G-clone 4 [ 1 0(3)­
D28 I G-4], 2 l PT-control vector 5 [2 I PT-V5], 2 I PT-p53-RI 75H-clone 22 [2 I PT-RI 75H-
22], 2 I PT-p53-R273H-clone 1 5  [2 I PT-R273H- 1 5] ,  2 I PT-p53-D2 8 I G-clone 46 [2I PT­
D28 I G-46], H l 299-control 5 [HC-5], H I 299-p53-D28I G-clone 5 [H-D28 I G-5], H 1 299-
p53-R273H-clone 14 [H-R273H- 1 4] ,  H I 299-p53-RI 75H-72 [H-R I 75H-72], p53-D28 1 G  
(L22Q/W23S)-clones I I , 1 3  and 1 9  [H-D2 8 I G  (L22Q/W23S)- I I , 1 3  and 1 9] ,  Saos-2 
control vector 2 and 4 [SC2 and SC4], Saos-2-p53-D28 I G  clones 1 4  and 25 [S-D28 I G-
1 4  and 25] and Saos-2-p53-D2 8 I  G (L22Q/W23S) clones 1 3  and 25 [S-D281  G 
(L22QIW23S)- 1 4  and 25] .  Additionally, stable pools of H l 299 expressing mutant p53-
R 1 75H, -R273H, -D2 8 1  G and -D281  G (L22Q/W23 S) were generated using the pIRES 
Pur03 expression vector from Clontech. Forty-eight hours after transfection the cells 
were subcultured 1 :4 and grown in selective medium containing neomycin (G4 1 8) at a 
concentration of 200 Ilg/ml [ 1 0(3)], 400 Ilg/ml [H1 299 and 2 I PT] or I mg/ml [Saos-2] to 
start the selection process. The medium was changed periodically and after three weeks 
of selection individual colonies were selected and analyzed for expression of p53 by 
Western blotting as described [ 1 9 1 ]  using the monoclonal antibody PAb l 80 1 .  Several 
clones from each transfection were expanded into cell lines. The H I 299 pools were 
generated using 2 Ilg/ml of puromycin. 
Murine 1 0(3) cells [ I I ]  or 1 0(3) cells stably expressing p53-D28 1 G  [ 1 34] were 
transfected with pCMVBam p53 del. 1 -293 and pCMVBam NEO [255] or pCMVBam 
p53 del. 1 -293 and pHyg (Clontech), respectively, using the calcium phosphate 
precipitation technique [ 1 88] .  Forty-eight hours after transfection, cells were washed, 
trypsinized, subcultured at I :4, and plated into selective medium supplemented with 200 
Ilglml G-4 l 8  (active concentration) for previously untransfected 1 0(3) cells and 200 
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flg/ml G-4 1 8  and 200 flg/ml hygromycin for p53-D28 1 G-expressing cells. Cells were 
maintained in the selective medium with twice weekly changes of medium. Cells from 
individual antibiotic-resistant colonies were isolated and expanded into cell lines. 
Cell culture. Human H 1 299 cells were maintained in RPMI 1 640 plus 1 0% Fetal 
Bovine Serum (FBS). 2 1  PT cells were maintained in a-MEM plus 1 0% FBS and 
indicated growth factors as described [262] .  Saos-2 cells were grown in DMEM plus 
1 0% FBS and 5% Calf Serum (CS). 1 0(3) cells were grown in DMEM plus 1 0% FBS. 
1 0(3) stable clones were grown in complete medium supplemented with the 
corresponding selection agent. 
Western blot analysis. Western blot analysis was carried out after SDS-PAGE using 
monoclonal antibodies against p53 (Oncogene, Ab-6, pAb 1 80 1 or pAb42 1 as indicated) 
or FLAG (Sigma) and a commercial kit (Promega) for labeling with an alkaline 
phosphatase-conjugated secondary antibody following the manufacturer's  protocol. 
Alternatively, proteins were detected using the ECL system (Amersham) following the 
protocol prescribed by the vendor. Actin was detected with a mouse monoclonal �-actin 
specific antibody (Sigma). C-myc was detected using a specific antibody (Oncogene, Ab-
1 )  and ASNS was detected using an antibody obtained from Dr. Michael Kilberg's 
laboratory. 
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Luciferase assay. Luciferase assays were carried olit using a commercial kit from 
Promega as suggested by the vendor, and luminescence was measured in a Luminometer 
made by Turner Designs. Cells were harvested 36-40hrs after transfection, and extracts 
were prepared as suggested. As described for the CAT assay, equal amounts of protein 
from each extract were used for the luciferase assay. Relative luciferase activity was 
plotted on the Y-axis and the value of the vector control was set to 1 00%. 
Glutaraldehyde cross-linking. Analyses for the presence of oligomeric forms of 
p53-D2 8 1 G  and its derivatives were carried out as described [23] .  Human p53-D28 1 G  
and its derivatives were generated by a coupled in vitro transcription-translation system 
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(Promega) and were incubated with glutaraldehyde at varying final concentrations at 
37°C for 1 5  minutes. After cross-linking, proteins were boiled in 2X Laemmli loading 
dye [23] ,  subjected to gradient (4-20%) SDS-PAGE, and visualized by autoradiography. 
Chloramphenicol acetyltransferase assay. Cells were harvested 36-40hrs post­
transfection and lysed by three successive cycles of freezing and thawing. Extracts were 
normalized for protein concentration and assayed for CAT enzyme activity as described 
earlier [ 1 55] .  Multiple independent experiments (three or more) were done to determine 
the standard deviations. CAT activity was detected by thin-layer chromatographic 
separation of [ 14C]-chloramphenicol from its acetylated derivatives followed by 
autoradiography. Quantitation was done using a Phosphorimager (Molecular Dynamics). 
In vivo labeling and immunoprecipitation. Saos-2 cells were transfected with p53 
expression plasmids (or expression vector alone) as indicated. Twenty-four hours post­
transfection labeling of cellular proteins was carried out with 35S-methionine for 2hrs 
after which cells were harvested and cell extracts prepared [ 1 88] .  Immunoprecipitations 
were carried out for 1 4hrs at 4°C using the indicated monoclonal antibodies [ 1 88] .  
PAb42 1 [263, 264] was used to bind p53 proteins with an intact C-terminus (intact p53-
D28 1  G as well as p53 del. 1 -293) and DO I [263, 264] was used to detect p53 proteins 
with an intact N-terminus (p53-D28 I G  but not p53 del. 1 -293). 
RNA isolation and microarray hybridization analysis. Total RNA was isolated 
from stably transfected 1 0(3) cells using Trizol (Gibco) reagent following manufacturer's 
protocol. Quality of the RNAs was checked by 1 .2% agarose TBE gel electrophoresis 
[236]. Microarray analysis from RNA from 1 0(3) cells stably transfected with ( 1 )  vector 
alone and (2) p53-D2 8 1  G was done by Incyte Genomics, Inc. (Palo Alto, CA) starting 
from whole RNA. Briefly, polyadenylated RNA was isolated with the OligoTex 
(Qiagen) RNA kit. Polyadenylated RNA was reverse transcribed to generate Cy3- and 
Cy5-labeled cDNA probes, respectively. cDNA probes were competitively hybridized to 
a mouse Unigene 1 cDNA microarray (lncyte Genomics, Inc.) containing immobilized 
cDNA fragments (average cON A length, 500-5000 base pairs). Cy3 and Cy5 
fluorescence were imaged individually, and the normalized ratios of Cy3/Cy5 
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fluorescence at a given spot on the microarray were used to calculate differential gene 
expressIOn. 
Quantitative real-time peR. Relative quantitation of gene expression was 
performed using quantitative real-time PCR (QPCR). The relative amount of each 
sample was calculated from a standard curve after employing a Fit Points algorithm. 
This expression value was normalized to a housekeeping gene, glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) [265] .  This method is described in detail by 
Johnson et al [266] and Tanguay et al. [267]. Following is a brief description of the 
entire process. 
(a) cDNA synthesis. Total RNA was isolated from stably transfected 1 0(3) cells 
using Trizol reagent (Gibco BRL) following the manufacturer's instructions. Ten 
micrograms of total RNA was treated with RQ I RNAse-free DNase (Promega), followed 
by phenol-chloroform extraction and ethanol precipitation. cDNA was synthesized with 
random hexamers using the Thermoscript RT-PCR System (Gibco BRL) according to the 
manufacturer's protocol. 
(b) Primers. Primers were designed using Oligo 5.0 Software (National Biosciences, 
Inc) and synthesized by Integrated DNA Technologies. Primer optimization was 
performed to determine the optimal concentration of MgCh and annealing temperature 
for each primer set. Relative standard curves were constructed for each target gene. 
Serial dilutions were made, and given arbitrary values corresponding to the dilutions. 
(c) Quantitative real-time PCR. Quantitative real-time PCR was performed using a 
LightCycler (Roche). Each reaction (20111) contained 2111 of the respective diluted cDNA, 
primers (0.5IlM), and 4mM MgCh, and FastStart Reaction Mix SYBR Green I, (Roche) 
which includes FastStart Taq DNA polymerase, reaction buffer, dNTPs, and SYBR 
Green I dye. A negative control was included in each QPCR run . 
Except for the composition of the standard curves, each reaction was performed in 
triplicate. Samples were investigated with murine GAPDH: 5 ' - CCA GCC TCG TCC 
CGT AGA CA -3' and 5'- GCC TCA CCC CAT TTG ATG ITA GTG -3', murine 
PCNA: 5 ' - GAT AAA GAA GAG GAG GCG GTA A -3' and 5 ' - ACA CGC TGG CAT 
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CTC AGG AGC A -3', and murine NF-KB2: S ' - TGG CCC CTA TCT GGT GAT TGT -
3' and S ' - ACA CTC CCA ACT CTG AAC ACT GCT -3'. Agarose gel electrophoresis 
and melting curve analysis were used to demonstrate the presence of a specific product. 
Colony formation assay. t o(3) cells stably transfected with the vector pCMVBam 
NEO [2SS] or stably expressing pS3-D28 1 G  [ 1 34] each in 1 0cm plates were transfected 
with I J.lg of pHyg and SJ.lg ( I )  pCMVBam [ 1 88], (2) pCMVBam WTpS3 [ 1 88], (3) 
pCMVBam FLAG-p73a [ 1 97], (4) pCMVBam FLAG-p73� Deb [ 1 97], or (S) 
pCMVBam pS3 del. 1 -293 [23] . Transfections were done by calcium phosphate 
precipitation technique as described earlier [ 1 34] .  After 48hr of transfection cells were 
subcultured 1 :4; hygromycin was added next day at 200 J.lg/ml to start the selection 
process. Neomycin (G4 1 8  at 200 J.lg/ml) was also added to those cells selected earlier for 
neomycin resistance as described before [ 1 34]. Every 2-3 days media were changed. 
After 3 weeks, cells were fixed with methanol and stained by methylene blue. 
Tumorigenicity assay. The tumorigenic potential of 1 0(3) cells expressing pS3 
derivatives was tested using nude mice. Cells (S x 1 06 per site) were subcutaneously 
injected into flanks of athymic nude mice (National Cancer Institute) and tumor 
development was monitored as described [ 1 1 ] ;  [ 1 34] . 
Immunoprecipitation. In vivo complex formation between pS3-D281  G and pS3 del. 
1 -293 in 1 0(3) cells stably transfected to express pS3-D281  G and pS3 del. 1 -293 was 
done by immunoprecipitation of pS3-D28 1 G  with an antibody (DO l )  that recognizes a 
motif on the N-terrninal part of the protein that is absent in pS3 del. 1 -293 . Cells from a 
1 0  cm dish were harvested in 4 ml of l OS buffer (containing 2S0mM HEPES, pH 7.2, 
I .S% NP40, O.S% Triton X- I OO, 0.02S% SDS, SOmM sodium phosphate buffer, pH 7.0, 
SmM NaF, O.SmM PMSF and 2.S mM DTI) as described. One ml of the extract was 
then incubated with 2J.lg ofpS3 antibody DOl and 1 6J.ll of protein A agarose (Invitrogen) 
and tilted overnight at 4°C. The following morning, the immunoprecipitate was washed 
three times with l OS buffer and once with a buffer containing 1 0mM Tris pH 7.S, SOmM 
NaCl, O.S% sodium deoxycholate and O.S% Triton X- t OO. The pellet was then 
suspended in 20 J.ll of 2X Laemmli loading buffer, boiled and analyzed by I S% SDS 
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polyacrylamide gel electrophoresis, followed by Western blot analysis using PAb42 1 as 
the probe. 
Chapter 4 Methods. 
Colony formation assay. 1 0(3) cells were plated at a density of 6 x 1 05 cells per 
plate in 1 0cm dishes 24 hrs prior to transfection and transfected using the calcium 
phosphate method as described earlier [ 1 88, 1 9 1 ] .  Cells were transfected with I Jlg of 
pCMVBam NEO and 5 Jlg ( I )  pCMVBam [ 1 88, 255], (2) pCMVBam WTp53, (3) 
pCMVBam p53-V I 43A, (4) pCMVBam p53-VI 57F, (5) pCMVBam p53-YI 63C, (6) 
pCMVBam p53-R I 75H, (7) pCMVBam p53-HI 79Y, (8) pCMVBam p53-Ll 94R, (9) 
pCMVBam p53-R273H, ( 1 0) pCMVBam p53-D28 I G, or ( I I )  pCMVBam p53-R282W. 
After 48 hr of transfection cells were subcultured I : 3 ;  neomycin (G4 1 8) was added next 
day at 200 Jlg/ml to start the selection process. Every 3-4 days the media was changed. 
After three weeks, the colonies formed were fixed with methanol and stained with 
methylene blue [ 1 9 1 ] . Only colonies containing more than thirty cells were counted. 
Purification of pS3. WTp53 was purified as described [ 1 95] .  Recombinant 
baculovirus expressing WT was used to infect SF9 cells. The virus was prepared as 
described [ 1 95] .  The protein was purified by affinity chromatography using a column of 
Affigel- I O  coupled with the purified monoclonal antibody PAb42 1 [268] .  Purity of the 
preparation was checked by SDS-PAGE and subsequent analysis by Coomassie [ 1 95] .  
Electrophoretic Mobility Shift Assay. Saos-2 cells were transfected using the 
calcium phosphate precipitation method [ 1 88] with an expression plasmid containing the 
cDNA for the WT or mutant p53 protein as indicated in the figure. After 48hrs, nuclear 
extracts were prepared following the method described in Yang et al [269] using a 
solution containing 20mM HEPES, pH 7.8; 25% glycerol; 520mM NaCI; 1 .5mM MgCb; 
O. l mM EDTA; 0.5mM DTT, 0.5mM PMSF; 2% Nonidet P-40; and protease inhibitor 
cocktail I (Calbiochem). The probes used were radiolabeled with [a32P]_dCTP using 
Klenow fragment of DNA polymerase I of E. coli (New England Biolabs). 
Approximately I OJlg of total protein [ 1 00ng of purified p53 [ 1 95, 270] in the control gel] 
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were incubated at 1 8°C for 30 minutes in binding buffer [4% glycerol, I mM MgCh. 
0.5mM EDTA, 0.5mM DTT, 50mM NaC!, 1 0mM Tris-HCL, pH 7.5, and I llg of poly 
dI:dC (Pharmacia)] with 5,000 cpm of radiolabeled probe. For the competition and 
supershifting studies, proteins were pre-incubated for 1 5  minutes in binding buffer with 
either an excess of unlabeled competitor oligodeoxynucleotide containing a p53-binding 
site (P2 1 WT) or a probe containing the same site mutated in two places to prevent 
binding of p53 (P2 1 MT). The labeled probes were added after the pre-incubation and the 
binding reactions were carried out as described above. The antibody DO I ,  specific for 
detecting p53, was used for supershifting. The extracts were then loaded into a 4% 
polyacrylamide gel and separated by electrophoresis at 200 volts at 1 2°C. The gel was 
dried and the presence of radioactively labeled DNA was detected by autoradiography. 
Probes used: I )  p2 I WT: 5'- GAT TCG TCA GGA ACA TGT CCC AAC ATG TTG 
AGC TCT GGA -3' and 5'- AGC TTC CAG AGC TCA ACA TGT TGG GAC ATG 
TTC CTG ACG -3'; p2 I MT: 5'-GAT TCG TCA GGA AAA TIT CCC AAA ATT TTG 
AGC TCT GGA -3' and 5'- AGC TTC CAG AGC TCA AAA TTT TGG GAA A TT TTC 
CTG ACG -3'. 
Transfections and luciferase assay. For transient transcriptional promoter assays 
human osteosarcoma (Saos-2) cells were cultured and transfected using Lipofectamine 
2000 (Invitrogen) in 24-well plates following the manufacturer's protocol. Each well 
was transfected with 200ng of the indicated promoter-Iuciferase construct and 25ng 
(p2 1 .Luc), 1 00ng (MDM2.Luc), 250ng (ASNS.Luc and hTERT.Luc), or 800ng 
(SV 40.Luc) of the p53 expression plasmid. Puc l 8  DNA was used as filler DNA up to 
I llg. Cells were harvested 36-48 hours after transfection, and extracts were prepared 
using Reporter Lysis Buffer (Promega). Equal amounts of protein from each extract were 
used for the luciferase assay. Value of the vector control was set to 100 and relative 
luciferase activity form the remaining samples calculated. All assays were repeated three 
times or more. 
Growth rate assay. Cells were seeded at a density of I x l 05 cells per 60-mm plate. 
Five plates of each cell line were plated initially. Whenever needed one plate of each 
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was trypsinized, and cells were suspended in I ml of serum containing medium; cells 
were counted each day using a hemocytometer and the total number of cells calculated 
and plotted. Media in the remaining plates were changed every day. Standard deviations 
were calculated from three independent experiments run simultaneously. 
siRNA transfection and cell viability assay. HI 299 cells (3x I 05) expressing pS3-
R I 7SH (H-RI 7SH-72) or vector alone (HC-S) were transfected by Lipofectamine 2000 
with siRNA directed against pS3 or a non-specific sequence (33nM final concentration) 
24hrs after plating. Cells were transfected a second time 24hrs later. Cells were then 
plated at equal density (3000 cells per well) 48hrs after the first transfection (Day 2) in 
96-well plates. Cell viability was measured using an MTS assay kit (CeIlTiter® 96 
Aqueous Non-Radioactive Cell Proliferation Assay Kit, Promega) for the following five 
days following the manufacturer's protocol. Mutant pS3 protein levels were detected 
using antibody PAb 1 80 I from a parallel experiment; p-actin (Sigma, AC- I S) was used as 
loading control. Cell viability was expressed as a percentage of HCS control cells 
transfected with the same siRNA. siRNA sequences used were: I )  control siRNA ( 'C') :  
S ' - CAU GUC AUG UGU CAC AUC UCT T -3'  and S ' - GAG AUG UGA CAC AUG 
ACA UGT T -3' 2) pS3 siRNA ('pS3') :  S ' - GCA UGA ACC GGA GGC CCA UTT -3'  
and S ' - AUG GGC CUC CGG UUC AUG CIT -3'  [ 1 98]. 
Drug sensitivity assays. HI 299 (or 2 I PT) cells stably expressing pS3-RI 7SH, -
R I 7SH (L22QIW23S), -R273H, -D28 I G, -D28 1 G  (L22QIW23S) or transfected with 
vector alone (as indicated in the figure), were plated at equal densities and treated with a 
final concentration of 3-61lM etoposide (Sigma) for 48hrs as specified in the text. 
Chemosensitivity of the cells was then measured by two different methods: ( l )  colony 
formation or (2) bromodeoxyuridine (BrdU) incorporation. Colony formation assay: 
Cells were plated at (Sx I 04 cellsll 0 cm dish) and exposed to a final concentration of 61lM 
etoposide for 48hrs. After treatment, plates were washed and the media replaced. The 
surviving cells were allowed to form colonies for 2-3 weeks with periodic changes of 
media. Colonies were fixed with methanol, stained with methylene blue and counted as 
described earlier [ l S6]. Control plates were plated at Sx I 03 cellsll 0 cm dish and treated 
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with an equal amount of DMSO. Control plates were assessed for plating efficiency and 
DMSO effects on cell growth. BrdU incorporation assay: Cells were plated at a density 
of I x l 06 in a 1 0  cm dish in the presence of etoposide (61lM final concentration) or 
DMSO as control for 4S-72h. Cells were incubated in the presence of I OIlM BrdU for 40 
minutes. After washing with Dulbecco's  Phosphate Buffer Solution (DPBS), cells were 
trypsinized, counted, fixed by vigorous vortexing and addition of cold absolute ethanol 
(ETOH) drop-wise. Cells were then stored at 4°C for at least I Shrs. Samples were 
washed with DPBS plus O.S% BSA to remove EtOH. Fixed cells were treated with 400 
III 2N HCI for 20 minutes, followed by incubation in O. I M sodium borate pH S.S for 2 
minutes. Samples were washed and resuspended in DPBS plus O.S% BSA and O.S% 
Tween 20 followed by incubation with anti-BrdU antibody coupled with fluorescein 
isothiocyanate (FITC) for 1 h in the dark with tilting. After washing to remove excess 
antibody, cells were resuspended in propidium iodide staining solution for at least I hr 
prior to fluorescence-activated cell sorting (F' ACS) analysis [27 1 ,  272]. Samples were 
gated for sub-G 1 DNA containing cells. 
Soft agar plating efficiency assay. Saos-2 cells expressing mutant pS3-D2S 1 G, the 
transactivation deficient pS3-D2S 1  G (L22QIW23S) or vector alone were plated at a 
density of 3000 cells/well over a .S% agar-medium plug. Assays were carried out in 6-
wel l  plates. Cells were plated in .2S% agar-medium for 4-S weeks with periodic 
additions of growth media. After four weeks, the colonies formed were counted under a 
light microscope. Colonies with an apparent cell number >30 were counted. The agar­
medium used in the assay contained the appropriate selection agents. 
Chapter 5 Methods. 
DNA microarray hybridization. Expression profiles of mutant pS3-expressing cells 
were compared with H 1 299 cells stably transfected with vector alone. Cells 
(approximately 3x 1 06 cells at the time of preparation) were plated 36-40hrs prior to RNA 
preparation. To compare to the mutant pS3 expression profiles, H 1 299 cells were also 
infected with recombinant adenovirus expressing WTpS3 and compared to cells infected 
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with adenovirus expressing p-galactosidase as a control. One culture (approximately 
3x l06 cells) per microarray sample was used. All microarray hybridization analyses were 
performed with biological duplicates of each mutant p53 expressing cell line using 
Affymetrix U95Av2 chips by either the GeneChip Core lab at UCSD or Virginia 
Commonwealth University's  institutional Nucleic Acid Research Facility. The U95Av2 
arrays represent 1 2,625 human gene sequences and expressed sequence tags (ESTs) 
previously characterized, in which each gene is represented by a probe set consisting of 
1 6-20 probes. The general procedures for microarray hybridization and analysis have 
been described elsewhere [273] .  
Data management and analysis. Data analysis was done using Affymetrix 
Microarray Analysis Suite version 4 (MAS 4). All arrays were normalized by a 
correction to a set value of median total hybridization intensity. Changes in gene 
expression were detected in terms of statistical significance of change in expression for a 
given gene between two compared microarrays (S-score) [ 1 99, 200). S-score analysis 
takes into account signals detected by 1 6-20 multiple probe pairs for individual genes, as 
well as intensity-dependent and -independent noise. The general procedures are 
described elsewhere [273) .  Briefly, the normalized files generated by the MAS 4 
software were analyzed by the S-score program [ 1 99) . Two hybridizations from each cell 
line were performed and changes in gene expression were detected in terms of S-score 
[ 1 99, 200). S-scores are derived to have a mean value of zero (representing no change) 
with a standard deviation of 1 .  Genes with an average intensity difference value of less 
than 50 in at least one sample were filtered out, resulting in 1 724 genes. The S-scores 
generated from our mutant p53-expressing cell lines were then analyzed for significance 
across replicate experiments by using a permutation method performed with the 
Significance Analysis of Microarray (SAM) program from Stanford University [20 1 ) .  
The settings for this analysis were: one-class response, unlogged data, and 300 
permutations, K-nearest neighbor imputer of 1 0  and a random number seed of 
1 23456789. Once the program reported the list of ranked genes, the "delta value" was 
adjusted to a stringent False Discovery Rate (FDR) of 0.3 %. Cluster analysis was done 
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using the Cluster and TreeView programs (http://rana.lbl.govl) to provide a graphical 
display of the expression patterns [256, 257] . Genes reported by SAM were analyzed by 
hierarchical clustering with average l inkage grouping. For our analysis the arrays 
themselves were not clustered. Functional grouping of the identified genes was done by 
manual editing of GeneOntology categories obtained through the DA VID annotation tool 
(http://david.niaid.nih.gov/david/ease.htm) [258]. 
Quantitative PCR (QPCR). QPCR was conducted using the LightCycier (Roche). 
Details of this method are described elsewhere [ 1 56]. Briefly, cDNA was synthesized 
using the Thermoscript RT-PCR system (Invitrogen). Primers were designed using Oligo 
5 (Molecular Biology Insights) and synthesized by Sigma Genosys. Reactions were 
performed in triplicate utilizing SYBR Green dye. . The degree of expression was 
quantitated using a relative standard curve and normalized to an internal control (BMV) 
corresponding to the cDNA batch [ 1 56]. Primer used were: 1 )  Asparagine synthetase 
(ASNS): 5' AGA GAT TCT CTG GCG ACC AAA AGA -3 ' and 5 ' - CTG GGT AAT 
GGC GIT CAA AGA CIT -3 ' ;  2) Angiopoietin J (ANGPTl ): 5 ' - GAT GTC AAT GGG 
GGA GGT T -3 ' and 5 ' - CTC TGA CTG GTA ATG GCA AAA ATA -3 ' ;  3) Cyclin B2: 
5 ' - CTG CCA CGC ITT ITC TGA TG -3 ' and 5'- GAC TTG TAC CAG CCA ATC 
CA -3 ' 4) c-myc: 5 ' - GCC GCC GCC AAG CTC GTC TCA GAG -3' and 5'- GCT GCT 
GGT GGT GGG CGG TGT CTC -3 ' ;  5) Asparaginyl-tRNA synthetase (NARS): 5 '- GCC 
GGA TGA GIT GTG TC -3 ' and 5 ' - ACC CCA AIT AGT TCC CAG AA -3' ;  6) RNA 
polymerase II, polypeptide E (RNA polII E): 5 ' - CCC ACC GAC CAG ATC ITT G -3' 
and 5'- GAC GAC GTG CTC AGG GAC TC -3 ' ;  7) Cell division cycle 25A (CDC25A): 
5'- AAG GCC CAT GAG ACT CIT -3' and 5'- AAA CIT GCC AIT CAA AAC AG -
3 ' ;  8) ras homologue gene family member G (rhoGAP): 5 '- AGT ACA TCC CCA CCG 
TGT TC -3' and 5 ' - GGA CTG GCA ATG GAG AAA C -3 ' ;  9) Apoptosis inhibitor 5 
(API5) :  5 ' - CCG ACC TAG AAC AGA CCT T -3' and 5 ' - GCC AAC AAT ITC AAT 
ACC TC -3' ;  1 0) Associated molecule with the SH3 domain ofSTAM (AMSH): 5 '- TAG 
ATG TGT TCC CAA CCT TA -3 ' and 5'- GIT GGC ACT GGC TAA CTG -3 ' ;  1 1 ) 
estrogen receptor binding protein site associated antigen 9 (EBAG9): 5 ' - TGC CIT 
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ITA ITC ATC AGT CIT C -3 ' and 5 ' - CGG CTG CTC TCT TIT CTC T -3 ' ;  1 2) 
integrin a6 (lTGA6): 5 ' - GTC CAG AGC CAA GGT CCA G -3 ' and 5 ' - CTC AAT 
CGC CCA TCA CAA AA -3 ' ;  1 3) minichromosome maintenance protein 6 (MCM6): 5 ' ­
ATC CCT CIT GCC AAG GAT IT -3'  and 5 ' - GAA AAG ITC CGC TCA CAA GC -
3 ' ;  1 4) transcriptionfactor E2F-5 (E2F-5): 5 ' - CCC CCA CCT GAT GAC CTC AC -3 ' 
and 5 ' - CTG CCG GGG TAG GAG AAA GC -3 ' ;  and 1 5) C-Syn proto-oncogene (C­
SYN): 5 ' - TGA ACA GCT CGG AAG GA -3' and 5'- CCC AAT CAC GGA TAG AAA 
GT -3 ' .  
Cloning of  presumptive promoters. Cloning of the presumptive gene promoters 
was done using genomic data sequence available in the NCBI database. Briefly, 
sequence specific primers were designed to amplify (by PCR) a genomic DNA fragment 
of up to I Kb upstream sequences containing the transcriptional start site for each of the 
promoters. Genomic DNA from MCF-7 cells was extracted using DNAzol reagent 
(Invitrogen) and used in the PCR reaction as template. Primers were designed using the 
Oligo 5 (Molecular Biology Insight) program. The PCR fragment was then purified and 
cloned into the pGL3 Luciferase reporter plasmid (Promega) using the indicated 
restriction enzymes. Sequences of the fragment were confirmed by DNA sequencing 
(Amplicon Express); clones bearing no base pair mutations were selected for further use. 
The following primers sets were use: I )  Angiopoietin I (ANGPTl ): 5 ' - CGG GGT ACC 
CAG GAG GIT TIT ATG TGG AA -3'  and 5 ' - CCC AAG CIT AAT GGC AGC GAG 
GAA -3' (KpnI and HindIII); 2) Integrin a6 (lTGA6): 5 ' - GGA AGA TCT AGC CIT 
CAT GCC ACC TAC AC -3' and 5 ' - CCC AAG CIT GCC ACC ITC GCC TCC TC -
3 '  (BglII  and HindIII); 3) Cyclin B2: 5 ' -CGG GGT ACC TGG GCT GAT TAT TAG 
ACG AA -3' and 5 ' - GGA AGA TCT ACG GGG AAG GCA AGA -3' (KpnJ and BglII) ;  
4) DNA polymerase delta subunit 2 (POLD2): 5'- CGG GGT ACC AGG CCC AGG 
GAA GTA GCA GA -3 ' and 5 ' - GGA AGA TCT GCC CAC CGA CCC AGG AG -3' 
(Kpnl and BglII); 5) Transcription factor E2F-5 (E2F-5): 5 ' - CGG GGT ACC ATG AAA 
ACC AAC CCT AAA ACT CCA -3' and 5 ' - CCC AAG CIT GAT CCA GAA CGC 
CGT CCT T -3' (Kpnl and HindIII). Luciferase constructs for the Asparagine synthetase 
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and EBAG9 were kind gifts of Michael Kilberg and Satoshi Inoue respectively [2 1 2, 
2 1 5] .  
Transfection and luciferase Assays. Luciferase assays were done as described 
[ 1 56]. Saos-2 (p53-null human osteosarcoma) cells were plated at equal density 24 hrs 
prior to transfection. Culture media was changed on the day of transfection. Cells were 
transfected with 1 00ng of the appropriate promoter-luciferase plasmids and 250ng of an 
expression plasmid (pCMVBam) for WTp53, p53-RI 75H, -R273H, -D28 1 G  -D28 1 G  
(L22QIW23S) or vector alone [ 1 56]. Cells were harvested 48hrs after transfection using 
Reporter Lysis Buffer (Promega). Luciferase activity was detected using a Luminometer 
from Turner Designs. Cell extracts were normalized based on total protein concentration; 
the vector reading was arbitrarily set to 1 00. Alternatively, cells were transfected with 
increasing concentrations of the expression plasmid for p52-R273H or -D28 l G and 
1 00ng of the ASNS promoter-luciferase construct. Assays were then conducted as 
described above. 
Adenovirus preparation and infection. A) The p53 (WT or mutant) gene was first 
cloned in a plasmid vector downstream of the human cytomegalovirus promoter, 
pZEROtg CMV. The viruses were generated by recombination in bacteria as described 
[274]. For control, we generated a recombinant adenovirus expressing �-galactosidase 
where the �-galactosidase gene is cloned downstream of the CMV promoter. In a 1 0  cm 
dish 3x 1 06 H 1299 cells [26 1 ]  were infected with the recombinant adenoviruses 
expressing WTp53,  p53-D28 1 G  or �-gahictosidase at an MOl of 5 .  The infection was 
conducted in the absence of serum. Total RNA was harvested at 24 or 48 hours after 
adenoviral infection from H1 299 cells using Trizol ( Invitrogen) reagent following 
manufacturer's protocol. Quality of the RNAs was checked by 1 .2% agarose Tris-borate­
EDTA gel electrophoresis. B) H1 299 cells were infected with increasing MOIs ( 1 ,  5, 1 0  
and 20) with a recombinant virus expressing p53-R273H (or �-galactosidase). Cell 
lysates were prepared 48 hrs after infection. Lysates were normalized based on total 
protein concentration and resolved by SDS-PAGE. ASNS was detected using an 
antibody specific for the protein (a kind gift from Dr. Michael Kilberg's laboratory). 
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Chromatin immunoprecipitation. Chromatin immunoprecipitations were done as 
described [2 1 6, 27S, 276]. Briefly, exponentially growing H1299 cells expressing mutant 
pS3-R273H ( l x l 07) were crosslinked with 1 %  formaldehyde for I S  minutes and the 
reaction stopped by addition of glycine to a final concentration of 0. 1 2SM for I S  more 
minutes. Cells were collected in and washed once with PBS, once with Wash buffer 1 
(0.2S% Triton X- l OO, l OmM EDTA, pH 8, O.S mM EGTA, pH7.S, HEPES, pH 7.S), 
once with Wash buffer 2 (0.2M NaCl, I mM EDTA, pH 8, O.SmM EGTA, pH 7.S, 1 0mM 
HEPES, pH 7.S) and lysed in SOOIlI of Lysis buffer ( l SOmM NaC!, 2SmM Tris-HCl, pH 
7.S, SmM EDTA, pH8, 1 %  Triton X- I 00, 0. 1 %  SDS, O.S% Sodium Deoxycholate). Cells 
were subjected to sonication and the chromatin sonicated to SOO- 1 00bp length fragments. 
DNA from approximately 2.Sx 1 06 cells was used in each immunoprecipitation. The 
immunoprecipitation volume was increased to I ml by addition of IP buffer (2S0mM 
NaC!, 2SmM Tris-HCl, pH 7.S, SmM EDTA, pH 8, 1 %  Triton X- I 00, 0. 1% SDS, 0.5% 
Sodium Deoxycholate), precleared with 30 III of protein A agarose (Calbiochem) and the 
indicated proteins immunoprecipitated overnight at 4°C with gentle tilting using specific 
antibody for pS3 or a control antibody (pS3, Oncogene, Ab-6; Normal rabbit IgG, Santa 
Cruz) following the manufacturer's recommendations. The antibody was captured the 
following day with I S  III of SO% slurry protein A agarose with gentle tilting at room 
temperature. The immunoprecipitate was pelleted and washed three times with 
Immunoprecipitation buffer, once with a High Salt wash (SOOmM NaCl, SOmM Tris-HCl, 
pH 8, 0. 1 % SDS, 1 % NP-40), once with a LiCI wash (800mM LiCl, SOmM Tns-HCl, pH 
8, O.S% Sodium Deoxycholate, 1 %  NP-40) and three times with I X  TE. The supernatant 
from the IgG immunoprecipitation was saved and labeled as input. The antibody-DNA 
complexes were eluted with two 200lli washes of Elution buffer (2% SDS, 1 0mM DTT, 
1 00mM NaHC03). The two elution fractions were combined and the crosslinking 
reversed by incubation at 6SoC for six hours. Ten nanograms of pGEM(3z)f- were added 
to each sample to act as an internal control and the DNA was then ethanol precipitated 
overnight. Samples were then dissolved in 1 80lll of I X  TE and RNAse ( l Ollg) and 
protease K (20llg) treated. Proteins were removed by phenol-chloroform extraction and 
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the isolated DNA ethanol precipitated overnight. The immunoprecipitated samples were 
dissolved in 1 2J.1l and the input sample in 200J.1l of I X  TE. QPCR was carried out as 
described above. The input DNA was diluted approximately 1 :  1 00 prior to PCR. 
Relative amounts of PCR product for the genes in this study were normalized to the 
relative amounts of the pGEM(3z)f- DNA in that sample and the Antibody/Input ratio 
calculated using the normalized amounts. The primers used were: 1 )  ASNS: 5'- AAT 
ITA ITT CGG TGC TG -3' and 5 ' - GAA GCC AAA ATA CAT CAG -3' 2) 
pGEM(3z)f- :  5'- GTA ATA CGA CTC ACT ATA GGG -3' and 5'- AIT TAG GTG 
ACA CTA TAG AAT AC -3' 
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P. Appendices 
Appendix A. 
The work presented in this appendix has not been published at the present time. It 
explores the role of the NF-KB2 gene in decreased chemosensitivity induced by mutant 
p53. This work was originally started by Katherine E. R. Stagliano and completed by 
myself. Although not directly related to the work in this dissertation, it includes and 
supports some of the data presented above. Only the results, figures, figure legends and 
methods sections from the manuscript are reproduced here in an edited form. 
Appendix B. 
During the process of writing this dissertation, new microarray data was generated 
using cell lines expressing the transactivation deficient mutant p53-D281  G (L22Q/W23S) 
derived from H1 299 cells. Presented here is a more comprehensive analysis of the 
microarray data presented above in conjunction with the newly generated data. Included 
is also data obtained from analyses of 2 1  PT cells expressing mutant p53-RI 75H, R273H 
or -D28 1 G. 
Appendix A. 
Tumor-derived pS3 mutants induce NF-KB2 gene expression. 
Mariano 1. Scian, Katherine E. R. Stagliano, Michelle A. E. Anderson, Saj ida 
Hassan' , Melissa Bowman' , Mike F. Miles' , Swati Palit Deb and Sumitra Deb. 
Department of Biochemistry and the Massey Cancer Center, , Department of Pharmacology and Toxicology, 
Virginia Commonwealth University, Richmond, VA 23298, USA. 
Experimental Results. 
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81299 and 2 1 PT cells expressing mutant p53 over-express a common set genes, 
including NF-KB2, which are inhibited or unaffected by WTp53. Since data 
described earlier suggested that mutant pS3-mediated transactivation is necessary for its 
growth promoting functions, microarray hybridization analyses of three H l 299-derived 
and three 2 1 PT-derived cell clones expressing pS3 mutants -RI 7SH, -R273H, and -
D28 1 G  were performed. The gene expression profiles of vector transfected H l 299 and 
2 1 PT cells were used as controls. Affymetrix U9SAv2 Arrays (HG-U9SAv2) 
representing -1 2,000 sequences were used. Changes in gene expression were detected as 
described earlier [ 1 99, 243] .  A common set of approximately I SO genes was found to be 
significantly upregulated by all three pS3 mutants in both the cell lines. Approximately 
1 00 of those genes were found to be inhibited or unaffected by WTpS3 but up-regulated 
in the presence of mutant pS3. (Table l A  shows a partial list). This common set of genes 
includes genes involved in cell growth, survival and adhesion (i.e. E2F-S, NF-KB2, 
integrin (16, etc.), often implicated in cancer. 
This up-regulation was verified by QPCR for a representative group of gene targets 
and expression of the triple mutant pS3-D28 1 G  (L22Q/W23S) in H l 299 cells did not 
result in up-regulation of the same genes [ 1 33]  (data not shown). Interestingly, the group 
of up-regulated genes includes a member of the NF-KB family, NF-KB2 (P 1 00/pS2), 
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which has earlier been shown by our laboratory to be up-regulated in murine 1 0(3) cells 
constitutively expressing tumor-derived p53-D28 1 G  [ 1 56] . Figure l A  (left panel) shows 
QPCR analysis demonstrating up-regulation of expression NF-KB2 (Pl 00/p52) in 
different mutant p53 expressing cell clones. This up-regulation was also confirmed by 
Western blot analysis using a specific antibody against NF-KB2 (P52) in the H1 299 
mutant p53-expressing cell lines (Figure l A; right panel) [ 1 56] . Expression levels ofNF­
KB I (P l 05/p50) were also determined by QPCR and found to be unaffected (Figure I A). 
NF-KB2 has been implicated in survival and anti-apoptotic functions in cells [208, 209] . 
It is possible then, that mutant p53 utilizes the NF-KB2 pathway to reduce drug 
sensitivity. 
Figure lA. Expression of mutant p53 up-regulates genes in H1 299 cells. 
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Specific NF-KB2 promoters are upregulated by mutant p53 in 91299. NF-KB2 
has been shown to have two different promoters (PI  and P2) both of which can be active 
in a cell [277] . Using promoter specific primers, PCR using the conditions described by 
Lombardi et at [277] with cDNA prepared from H1 299 cells expressing p53-R1 75H or 
vector control (HC-5) was performed. The data shown in Figure 2A demonstrate that in 
H1 299 cells mutant p53 up-regulates NF-KB2 (P l 00/p52) expression using the P2 
promoter, whereas the P I  promoter remains unaffected. 
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Figure 2A. Mutant p53 up-regulates NF-KB2 using the P2 promoter in H1 299 cells. 
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Mutant p53 transactivates the NF -KB2 P2 promoter in vivo. After ascertaining 
that mutant p53 up-regulates the P2 promoter of NF-KB2 (PI OO/p52), the P2 promoter 
sequences were cloned upstream of the luciferase gene in pGL3 vector as described in 
Materials and Methods using published sequence information [277] . Transient 
transcriptional assays were carried out in p53-null Saos-2 cells. Transcriptional results 
shown in Figure 3A-a demonstrate that tumor-derived p53 mutants p53-RI 75H, -R273H 
and D28 l G  transactivate the NF-KB2 P2 promoter, while WTp53 represses, in agreement 
with our in vivo expression data. Furthermore, transfection of cells with mutant p53-
D28 1 G  (L22Q/W23S) did not show up-regulation of the NF-KB2 P2 promoter (Figure 
3A-a). 
The NF-KB pathway is activated in cells expressing mutant p53. To determine 
whether expression of mutant p53 results in activation of the NF-KB pathway, NF-KB­
specific transcription was assayed using a synthetic construct containing five NF-KB­
binding sites upstream of a TAT A box cloned upstream of a luciferase reporter gene 
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[278] .  If the NF-KB pathway is active, more NF-KB2 should result in higher promoter 
activity in cells expressing the p53 mutants. 
Figure 3A. Mutant p53 up-regulates NF-KB2 P2 promoter. 
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As expected, cells expressing mutant p53-RI 75H, -R273H and -D28 1 G  had higher 
promoter activity in comparison with the HC-5 (stably transfected with vector alone) cell 
line (Figure 3A-b) demonstrating that the NF-KB pathway is more active in cells 
expressing mutant p53 and that this activation is dependent on transactivation by turnor­
derived p53 mutants. Western Blot analysis showed similar levels of expression of p53 
in these cells (Figure 3A-b, right inset). Interestingly, at least one of the mutant p53 
target genes, c-myc, has also been found to be a target of NF-KB suggesting the 
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possibility that mutant p53 may be transactivating c-myc through NF-lCB [279]. 
However, it is also possible that both mutant p53 and NF-lCB independently up-regulate 
c-myc expression. Protein expression levels of ReI A and c-Rel, two other members of 
the NF-KB protein family was also examined. Western blot analysis using extracts from 
vector control H 1 299 cells (HC-5) and H1 299 cells expressing mutant p53 show no 
appreciable difference at the protein level for either of these proteins (data not shown). 
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Figure 4A. H1 299 cells expressing mutant p53-R1 75H show increased NF-K8 
binding. 
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0 1 299 cells expressing mutant p53 show increased NF -KB DNA binding. EMSAs 
were performed to determine whether NF-KB binding activity changed in cells expressing 
mutant p53 compared to the control cells. Nuclear extracts from HC-5 control and 
mutant p53-R1 75H expressing H1299 cells were prepared and binding reactions 
performed using double-stranded DNA oligonucleotide probe containing the NF-KB 
DNA binding site as described [236, 280, 28 1 ] .  The experimental data obtained suggest 
that there is an increase in DNA binding activity in cells expressing the mutant p53-
9 1  
R17SH (Figure 4A, single arrows indicate NF-KB complexes). Antibody supershift using 
specific antibodies against pSO or pS2 suggests that the complexes formed contain pSO or 
pS2 (double arrow). This supershift is not observed in the presence of antibody alone 
(lanes 1 7- 1 9). Thus, data shown so far indicate that mutant pS3 expression leads to an 
activation of the NF-KB pathway. In parallel, using a WTpS3 ecdysone (Ponasterone A) 
inducible cell line [282], similar DNA binding reactions were carried out. Induction of 
WTpS3 resulted in increased DNA binding. Unlike in the case of mutant pS3 expressing 
cells, these complexes contained pSO in agreement with the results reported by Bohuslav 
et af [283] but not pS2 (compare lanes 1 2- 1 S  with 24-27). Sp 1 and pS3 were detected to 
determine equal loading of protein and proper WTpS3 induction using specific antibodies 
as indicated (data not shown). 
Over-expression of NF-KB2 in 9 1299 cells leads to loss of sensitivity to etoposide. 
The human NF-KB2 (P l 00/pS2) gene [284] was cloned into pIRESpur03 (Clontech), a bi­
cistronic expression vector under the CMV immediate-early promoter where the NF-KB2 
gene shares the same promoter with the puromycin resistance gene. Because of the bi­
cistronic nature of this cloning vector, most of the puromycin-resistant colonies express 
the gene of interest. Using this NF-KB2 expression plasmid and the empty expression 
vector pools of H1 299, cells expressing NF-KB2 (or stably transfected with vector alone) 
were generated (Figure SA, right panel). 
Figure SA. Expression of NF-KB2 confers H1 299 cells with a decreased sensitivity to 
etoposide. 
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Cells were exposed to 6JlM etoposide (final concentration) for 48hrs as before. Over­
expression of NF-KB2 in these cells led to an increase in the number of surviving cells 
compared to the vector control cell line (Figure SA, left panel). The data presented 
demonstrate that NF-KB2 over-expression in H I299 cells imparts a lack of sensitivity to 
etoposide. That mutant pS3 expression in H I 299 cells leads to induction of NF-KB2 
expression as well as lack of sensitivity to etoposide suggests that mutant pS3 
desensitizes the cells to etoposide via the NF-KB2 signal transduction pathway. 
Figure 6A. siRNA against NF-KB2 increases the sensitivity of cells to etoposide. 
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NF-KB2 specific siRNA reduces the level of NF-KB2 in 91299 cells expressing 
p53 and inhibits mutant p53-induced lack of sensitivity towards etoposide. 
Observations reported in Figures I ,  3, S and 7 suggest that mutant pS3 may increase 
chemoresistance of cells by inducing over-expression of NF-KB2. We tested this notion 
by using siRNA capable of reducing expression of NF-KB2 specifically and determined 
whether this would lead to increased etoposide sensitivity in H I 299 cells expressing 
mutant pS3 (-R I 7SH). We reasoned that a decrease in NF-KB2 protein levels during the 
incubation period with etoposide would increase the sensitivity of the cells to the drug. 
Two different siRNAs against NF-KB2 were used. After transfection of siRNA specific 
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for NF-KB2, the level of NF-KB2 protein is significantly reduced (Figure 9B). The 
parallel nonspecific siRNA had little or no influence (data not shown). 
A reduction in NF-KB2 level led to a reduction in the number of surviving cells 
(colonies formed) after etoposide regardless of the p53 status in the cells. The average 
number of colonies formed is depicted in the figure. In parallel, cells transfected with the 
same siRNAs were plated and treated with vehicle (DMSO) as indicated in Materials and 
Methods. Plating efficiency differed by less than 10% (data not shown). The siRNA 
experimental data corroborates our idea that at least one pathway through which mutant 
p53 induces chemoresistance in cancer cells is by up-regulating expression of genes such 
as NF-KB2. 
Figure Legends. 
Figure lAo Expression of mutant p53 up-regulates genes in 0 1 299 cells. Left: 
cDNA from mutant p53 expressing H I 299 cells analyzed by QPCR using gene specific 
primers for NF-KB I and NF-KB2 expression. NF-KB2 but not NF-KB I is up-regulated 
by mutant p53. Right: Western blot demonstrating up-regulation of NF-kB2 in mutant 
p53-expressing H I 299 cell lines and a murine cell line [ l 0(3)] stably transfected to 
express mutant p53-D281  G. Cell extracts were prepared using Reporter Lysis Buffer 
(Promega). NF-kB2 was detected using a specific antibody as specified in Materials and 
Methods 
Figure 2A. Mutant p53 up-regulates NF-KB2 using the P2 promoter in 0 1 299 
cells. Using promoter specific primers, PCR was conducted using the conditions 
described by Lombardi et at [277] with cDNA prepared from clones of H I 299 cells 
expressing mutant p53-R1 75H (or the vector control cell line HC-5). PCR primers are 
designed to detect mRNA products resulting from the two NF-KB2 promoters. PCR 
reactions were performed in duplicate. The data shown demonstrates that in H 1299 cells 
mutant p53 up-regulates NF-KB2 using the P2 promoter, whereas the PI promoter 
remains unaffected. 
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Figure 3A. Mutant pS3 up-regulates NF-KB2 P2 promoter. a. Saos-2 cells were 
transfected with 200ng of pGL3 vector containing the NF-kB2 P2 promoter upstream of 
the luciferase reporter gene, 200ng of Renilla luciferase (TK.Renilla.luc) control plasmid 
and 600ng of the indicated pS3 expression plasmid. Cells lysates were prepared 48hrs 
after transfection and luciferase activity detected using the Dual Luciferase Reporter 
Assay System (Promega). Reporter luciferase readings were normalized based on 
TK.Renilla.luc control plasmid readings. Fold induction for pS3-RI 7SH, -R273H and 
D28 l G, respectively. b. H 1 299 cells expressing mutant pS3-RI 7SH, -R273H, -D281  G, -
D28 1  G (L22QIW23S) or vector alone were transfected with SOOng of a reporter plasmid 
containing five NF-KB sites. Cells were harvested 48hrs after transfection, lysates 
prepared and luciferase activity detected. Cell extracts were normalized based on total 
protein concentration; the vector reading was arbitrarily set to 1 00. Inset shows western 
blot analysis demonstrating similar levels of pS3 expression in the cell lines. Protein 
amoUnts were normalized based on total protein concentration. 
Figure 4A. 8 1299 cells expressing mutant pS3-R17S8 show increased NF-KB 
binding. Nuclear extracts of HC-S and H-R 1 7SH were incubated as described in 
Materials and Methods with a 32P-labeled probe containing the NF-KB DNA binding site 
sequence. Competition studies were done using a specific competitor (SC, lanes 4-7) 
and a non-specific competitor (NSC, lanes 8-1 1 )  in 20x and 40X molar excess (lanes 4-
7). The single arrow indicates the DNA complexes containing NF-KB complexes. 
Increased NF-KB activity is observed in the presence of mutant pS3 (lanes 2-3, 8- 1 1 ). 
The double arrow indicates the supershifted complex in the presence of an antibody 
specific for NF-KB I (PSO), NF-KB2 (PS2) or pS3 (lanes 1 2- 1 S ,  20-2 1 ,  24-29). Equal 
amounts of protein were added to each lane. 
Figure SA. Expression of NF-KB2 confers 8 1299 cells with a decreased 
sensitivity to etoposide. H1 299 cells stably expressing NF-KB2 were treated with 61lM 
etoposide final concentration for 48hrs. After treatment the surviving cells were washed 
and allowed to form colonies for three weeks with periodic changes of media. Colonies 
were then fixed in methanol, stained and counted. The data shown are representative of 
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three independent experiments; colony numbers were adjusted to account for plating 
differences based on control plates. Control plates were plated at one-tenth the density 
and treated with DMSO. Expression of NF-KB2 protein was checked by western blot 
(Right). Actin was used as a loading control. 
Figure 6A. siRNA against NF-KB2 increases the sensitivity of cells to etoposide. 
H l 299 cells expressing mutant p53-R1 75H (or the control cell line HC5) were plated at 
equal densities in 1 2-well plates. Cells were transfected 24 and 48hrs after plating using 
siRNAs against NF-KB2 (or a non-specific control) and plated as described in Materials 
and Methods 24hrs after the second transfection. Cells were then exposed to 6JlM 
etoposide (final concentration) or vehicle control (DMSO) for 48hrs. Cells were allowed 
to grow and form colonies. Colonies were then fixed with methanol, stained with 
methylene blue and counted. A. Graphical representation of the results. The average 
number of colonies formed is depicted in the figure. Plating efficiency differed by less 
than 1 0% (data not shown). B. Western blot analysis of cells from a parallel experiment 
transfected with siRNAs to evaluate the effectiveness of the RNAi constructs. Actin was 
used as a loading control. 
Experimental Methods. 
Generation of stable cell lines. Stable cell lines were generated after transfection of 
p53-null H 1 299 and 21 PT cells with mutant p53 expression plasmids (or expression 
vector alone), containing a neomycin resistance gene as described [ 1 34]. The following 
p53 mutant cell lines were generated: p53-RI 75H, p53-R273H and p53-D28 l G  using 
G41 8  selection (400 Jlg/ml for H l 299 cells and 500 Jlg/ml for 2 1 PT cells). The p53-
D28 1 G  (L22QIW23S) clones were only generated in H l299 cells. H l 299 cells were 
also transfected with pIRES-puro3 vector alone or pIRES-pur03 containing NF-KB2, 
p53-RI 75H, p53-R273H, p53-D28 1 G  or p53-D28 1 G  (L22Q/W23S) cDNA. Cells were 
selected with 2.5Jlg/ml of puromycin for two weeks. The resulting colonies were then 
pooled and used for further assays. 1 0(3) cell clones were generated earlier at 200 Jlg/ml 
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G4 1 8  [ 1 34) . Hip53, a wild-type p53 inducible cell line, was generated earlier [282) . 
None of the cells lines used in our assays Saos-2, H1 299, 2 1 PT or 1 0(3) express 
detectable p53 [ I I ,  1 28, 1 33 ,  262). 2 1 PT expresses an N-terminally truncated and 
functionally inactive p53 [285). 
Recombinant adenoviruses, adenoviral infection and RNA preparation. 
Recombinant adenoviruses expressing WTp53 and �-galactosidase were generated by the 
laboratory of Dr. Kristoffer Valerie, Massey Cancer Center (Richmond, Va) and by the 
lab of Atsushi Miyanohara, UCSD Gene Therapy Program. In a 1 0  cm dish 3x 1 06 cells 
were infected with the recombinant adenoviruses expressing either WTp53 or �- . 
galactosidase at 1 0  multiplicity of infection (MOI)/cell ratio. At 20 hours, RNA was 
extracted for microarray analysis. Total RNA was isolated using Trizol (Invitrogen) 
reagent following the manufacturer's  recommendations and checked by 1 .2% agarose 
Tris-borate-EDT A gel electrophoresis. 
Drug sensitivity assays. HI 299 (or 2 I PT) cells stably expressing p53-RI 75H, -
R I 75H (L22Q/W23S), -R273H, -D281  G, -D28 1 G (L22Q/W23S) or transfected with 
vector alone (as indicated in the figure), were plated at equal densities and treated with a 
final concentration of 3-6J.lM etoposide (Sigma) for 48hrs as specified in the text. 
Chemosensitivity of the cells was then measured in two different ways: ( l )  colony 
formation after 2-3 weeks, and (2) bromodeoxyuridine (BrdU) incorporation. Colony 
formation assay: Cells were plated at a density of 5x I 04 cells in 1 0cm dishes and 
exposed to a final concentration of 6J.lM etoposide for 48hrs. After treatment, plates were 
washed and the media replaced. The surviving cells were allowed to form colonies for 2-
4 weeks with periodic changes of media. Colonies were fixed with methanol, stained 
with methylene blue and counted as described earlier ( 1 56). Control plates were plated at 
a density of 5x 103 cells in 1 0  cm plates and treated with an equal amount of dimethyl 
sulfoxide (DMSO). Control plates were assessed for plating efficiency and DMSO 
effects on cell growth. BrdU incorporation assay: Cells were plated at a density of I x I 06 
in a I Ocm dish in the presence of etoposide (6J.lM final concentration) or DMSO as 
control for 48-72h. Cells were incubated in the presence of 1 0J.lM BrdU for 40 minutes. 
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After washing with Dulbecco's Phosphate Buffer Solution (DPBS), cells were 
trypsinized, counted, fixed by vigorous vortexing and addition of cold absolute ethanol 
(ETOH) drop-wise. Cells were then stored at 4°C for at least 1 8hrs. Samples were 
washed with DPBS plus 0.5% BSA to remove EtOH. Fixed cells were treated with 400 
III 2N HCl for 20 minutes, followed by incubation in 0. 1 M sodium borate pH 8.5 for 2 
minutes. Samples were washed and re-suspended in DPBS plus 0.5% BSA and 0.5% 
Tween 20 followed by incubation with anti-BrdU antibody coupled with fluorescein 
isothiocyanate (FITC) for I h  in the dark with tilting. After washing to remove excess 
antibody, cells were re-suspended in propidium iodide staining solution for at least I hr 
prior to florescence-activated cell sorting (FACS) analysis [27 1 ,  272] . Samples were 
gated for sub-G 1 DNA containing cells. 
siRNA transfection. H I 299 cells expressing mutant p53-R1 75H (or the control cell 
line HC-5) were plated at equal densities in 1 2-well plates (3 x 10\ Cells were 
transfected 24 and 48hrs after plating using siRNA against NF-KB2 (or a non-specific 
control). Sequences used were: Control (siControl): 5'- CAU GUC AUG UGU CAC 
AUC ACT T -3'and 5 ' - GAG AUG UGA CAC AUG ACA UGT T -3 ' ,  NF-KB2 
(siNFkB2 # 1 ): 5 ' - GAC AAG GAA GAG GUG CAG CIT -3 ' and 5 ' - GCU GCA CCU 
CUU CCU UGU CIT -3 ' and NF-KB2 #2 (siNFkB2 #2): 5 ' - GCC CUG AGU GCC 
UGA AUC U -3'  and 5 ' - AGA UCC AGG CAC UCA GGG CIT -3' .  Twenty-four 
hours after the second transfection, cells were trypsinized, counted and plated in 1 0  cm 
plates at a density of 5x 1 04 cells per plate (control plates were plated at a density of 5x 1 03 
cell per plate). Cells were then treated with 61lM etoposide (final concentration) or 
equivalent vehicle control (DMSO). Cells were allowed to form colonies for 2 to 4 
weeks. Colonies were then fixed with methanol, stained with methylene blue and 
counted as described earlier [ 1 56]. 
DNA microarray hybridization, data management and analysis. Expression 
profiles of mutant p53-expressing cells were compared with H 1 299 (or 2 1  PT) cells stably 
transfected with vector alone. Cells infected with recombinant adenovirus expressing 
WTp53 were compared to cells infected with adenovirus expressing �-galactosidase as a 
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control. All mlcroarray hybridization analyses were performed In duplicate using 
Affymetrix U95A v2 chips by either the GeneChip Core lab at UCSD or Virginia 
Commonwealth University's  Institutional Nucleic Acid Research facility. U95Av2 Array 
represents -1 2,000 human gene sequences that have been previously characterized. The 
general procedures for microarray hybridization and analysis are described elsewhere 
[273] .  Data analysis was done using Affymetrix Microarray Analysis Suite 5 (MAS 5). 
Changes in gene expression were detected in terms of statistical significance (S-score) of 
change in expression for a given gene between two compared microarrays. S-score 
analysis takes into account signals detected by 1 6  multiple probe pairs for individual 
genes, as well as intensity-dependent and -independent noise [ 1 99]. Briefly, the files 
generated by the Affymetrix software were first filtered to eliminate genes with an 
average intensity value less than 50 in at least one of the samples, resulting in 24 1 7  genes 
for further study. The filtered data was then analyzed with the S-score program. S-scores 
are derived to have a mean value of zero (representing no change) with a standard 
deviation of I .  The S-scores generated were then analyzed for significance across 
replicate experiments by using a permutation method performed with the significance 
analysis of microarray (SAM) program from Stanford University [20 I ] .  The settings for 
this analysis were: unlogged data, 300 permutations, K-nearest neighbor imputer of 1 0  
and a random number seed o f  1 23456789. Once the program reported the list o f  ranked 
genes, the "delta value" was adjusted to a stringent False Discovery Rate (FDR) of 0.3% 
resulting in the identification of 149 genes upregulated by all three p53 mutants in both 
cell lines. Clustering analysis was done using the Cluster and TreeView programs 
(http://rana.lbl.govl) to provide a graphical display of the expression patterns [256]. 
Genes reported by SAM were analyzed by hierarchical clustering with average linkage 
grouping. For our analysis the arrays were not clustered. Functional grouping of the 
identified genes was done by manual editing of Gene Ontology categories obtained 
through the DAVID annotation tool (http://david.niaid.nih.gov/davidlease.htm) [258]. 
Quantitative peR. QPCR was conducted using the LightCycler (Roche) as 
described [286]. cDNA was synthesized using the Thermoscript RT-PCR system 
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(Invitrogen). Primers were designed using Oligo 5 (Molecular Biology Insights) and 
synthesized by Sigma Genosys. Reactions were performed in triplicate utilizing SYBR 
Green dye, which exhibits a higher fluorescence upon binding of double-stranded DNA. 
The QPCR primers used were, NF-KB2: 5' - GGG GCA TCA AAC CTG AAG AIT TCT 
-3' and 5 ' - TCC GGA ACA CAA TGG CAT ACT GT -3' ;  NF-KBl : 5' - CAC ITA GCA 
ATC ATC CAC CIT -3' and 5 ' - AGC CCT CAG CAA ATC CT -3' .  
NF-KB2 Promoter PCR. NF-KB2 promoter PCR was performed using the 
conditions described by Lombardi et at. [277] with cDNA prepared form HI 299 cells 
expressing mutant p53 (or the control cell line HC-5). The promoter specific primers 
used were: P I : 5 ' - AGA GCA GCA GCT GCA CAC AG -3 ' and 5'- GCT CTG TCT 
AGT GGC TCC -3 ' ;  P2: 5 ' - AAC TCC GGA TCT CGC TCT CC -3' and 5'- GCT CTG 
TCT AGT GGC TCC -3' .  Note that the reverse primer for the P I  and P2 promoters is 
the same; while the forward primer is different, thus generating two distinct PCR 
products of 1 53 bp (P I )  and 1 1 6 bp (P2). 
Cloning of presumptive promoter. The presumptive promoter 2 (P2) sequence of 
NF-kB2 was cloned in the pGL3 basic vector upstream of the luciferase gene using the 
available genomic sequences in the NCBI database and genomic PCR using a 
commercial kit (Invitrogen). The primers used were: 5 ' - CGC TAG CAA CTC GCG 
CCT GGT GTC CGT -3'  and 5 ' - CCA AGC TTG CGG CAT GAC TCA CTG GGT 
TGT AG -3' (forming NheI and BglI I  sites at the ends, respectively). The restriction 
enzymes in parenthesis indicate the location of the insert in the multiple cloning site of 
the pGL3 reporter vector. The P2 promoter was cloned using Saos-2 cells, and contains a 
single mismatch (A to G). We found the same mismatch in multiple analyzed clones and 
did not investigate any further. It should be noted though, that an analysis with the 
program TFSEARCH (http://www.cbrc.jp/researchidbITFSEARCH.html) indicates that 
the sequence does not fall  on any known transcription factor-binding site (not shown). 
Transient transcriptional assays. Promoters were tested by transient transcriptional 
assays using p53-null Saos-2 (human osteosarcoma) cells. Transfections and luciferase 
assays were carried out as described [ 1 56]. Saos-2 cells were plated at equal densities in 
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24-well plates and transfected with 200 ng of the promoter luciferase construct, 200 ng of 
Renilla luciferase control (TK Renilla.luc, used for normalization of transfection) and 
500 ng of the corresponding p53 expression plasmid 24hrs after plating. H I 299 cells 
stably expressing mutant p53 were plated at a density of 3x I 05 cells/well in 6-well plates 
and transfected with 500 ng of a reporter plasmid containing NF-KB sites upstream of the 
luciferase gene (kind gift from Dr. Valentine Andela of the University of Rochester) 
[278] .  Transfections were carried out using the Lipofectamine 2000 reagent (Invitrogen) 
following the manufacturer's recommendations. Cell lysates were prepared 48hrs after 
transfection using Reporter Lysis Buffer (Promega). Luciferase activity was detected 
using a Luminometer from Turner Designs. Transcriptional assays were repeated at least 
three times. 
Electrophoretic mobility shift assay (EMSA). Nuclear extracts were prepared in the 
following manner. Cells grown to confluency were washed twice in PBS and lyzed in 
700 �l of Digriam buffer [28 1 ]  [ 1 0  mM HEPES pH 7.9, 1 .5 mM MgCh, 10  mM KCI, 0.5 
mM DTT, 1 %  Nonidet P-40, 0.5 mM PMSF, plus protease inhibitor (cocktail III from 
Calbiochem)] by adding the buffer directly onto the plate and incubating on ice for 20 
minutes. Cells were then scraped and transferred into a pre-chilled eppendorf tube and 
further incubated on ice for 20 minutes. Nuclei were then pelleted at 4000 rpm, 4°C for 
1 0  minutes, the supernatant (cytoplasmic extract) stored at -80°C. The nuclei were 
resuspended in 1 00 �I Nuclear extraction buffer [(20 mM HEPES pH 7.9, 25% glycerol, 
1 .5 mM MgCh, 0.5 mM DTT, 0. 1 mM EDTA, 1% Nonidet P-40, plus protease 
inhibitors] and incubated on ice for I hour. The samples were pelleted at 1 0,000 rpm, 
4°C for 1 0  minutes and the supernatant (nuclear extract) stored at -80°C. Protein 
concentrations were determined using Biorad's Protein assay reagent and equal amounts 
of protein were used in each binding reaction. EMSAs were performed as described 
[283] using 1 5�g of nuclear extract protein per binding reaction. Reactions were pre­
incubated at 25°C for 20 minutes prior to the addition of the oligonucleotide probe. After 
pre-incubation, approximately 20,000 counts of labeled probe were added to each 
reaction tube and incubated at 25°C for an additional 20 minutes. For the supershift 
1 0 1  
experiments, antibodies ( l  Jlg) were added after incubation with the probe and incubated 
for an additional 1 5  minutes. Samples were then loaded and complexes separated on a 
6%, 0.5X Tris-Borate-EDTA gel run at 200volts for approximately 1 .5-2hrs. The gel was 
then fixed, dried and exposed to film. Probes were annealed and 32p_dCTP labeled using 
Klenow fragment as described [236). The oligonucleotide sequences used were: Wild­
type (WT) 5' - GAT CCG AGG GCT GGG GAT TCC CAT CTC CCA CGT TIC ACT 
TCA -3 ' and 5 ' - AGC TIG AAG TGA AAC GTG GGA GAT GGG AAT CCC CAG 
CCC TCG -3' ;  Mutant (MT) 5 ' - GAT CCG AGG GCT TTT TAT GAA AAT CTC CCA 
CGT TIC ACT TCA -3' and 5 ' - AGC TIG AAG TGA AAC GTG GGA GAT TTT 
CAT AAA AAG CCC TCG -3 ' .  For competition studies an unlabeled WT probe was use 
as the specific competitor (SC) and the MT probe as the non-specific competitor (NSC) at 
20X and 40X molar excess. Hip53 cells were induced with 10JlM Ponasterone A. NF­
KB 1 (P50), NF-KB2 (P52) and p53 specific antibodies were used for the supershift 
experiment (Santa Cruz, sc- 1 1 4X; Rockland, cat# 4 1 85 ;  Oncogene, Ab-6, respectively). 
Western blotting. NF-KB2 and Spl levels were detected using antibodies from 
Santa Cruz Biotechnologies (sc-7386 and sc-59 respectively). Actin levels were detected 
using an antibody from Sigma (AC-1 5). NF-kBl (P 1 05/p50), Rei A and c-Rel were 
detected using an antibody kit from Calbiochem (cat# ASK20). p53 was detected using 
the p53 antibody PAb 1 80 1 .  Western blots were developed by the ECL method 
(Amersham). In western blots for the siRNA and colony forming assay the H-IRES NF­
KB2 (P1 00/p52) cell line, NF-KB2 protein was detected using an antibody from Upstate 
Biosciences (cat # 05-36 1 ). 
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Appendix B. 
The microarray data generated was analyzed as before [236, 243] .  S-cores generated 
by comparing hybridization signals from mutant p53 expressing cell lines and the 
corresponding controlled were analyzed for significance across replicates. The data were 
analyzed using the following SAM settings: multiclass analysis, 300 permutations, K­
nearest neighbors imputer of 1 0, and a random seed number of 1 23456789. This type of 
analysis identifies genes that are differentially regulated between groups of data. In this 
case, data from H I 299 cells expressing mutant p53 was labeled as group I ;  data from 
2 1 PT cells was labeled as group 2;  and data from cells expressing the transactivation 
deficient p53-D28 1 G  (L22Q/W23S) was group 3. The FDR was set to 0.025%. The 
Cluster and Tree View programs were used to generate a visual representation of the 
results. 
There are several, striking features to this figure regarding the modulation of gene 
expression by mutant p53 in H I 299 and 2 1 PT cells. First, a larger number of genes is 
up-regulated by mutant p53 rather than down-regulated. This suggests that up-regulation 
of genes by mutant p53 may play a significantly more important role than down­
regulation of genes in mutant p53 oncogenicity. Second, genes up-regulated in the 
H I 299 cells by the transactivating forms of mutant p53 are repressed (Cluster I )  or 
unaffected (Clusters 3) by the transactivation deficient mutant p53-D28 1  G 
(L22/QIW23S). 
Thirdly, a number of genes are up-regulated by the mutant proteins regardless of their 
transactivation status (Cluster 3). This suggests that perhaps some transcriptional up­
regulation may be due to factors other than the transactivation ability of mutant p53, such 
as protein-protein interactions. Also, it appears that genes repressed in H 1 299 cells are 
up-regulated by the transactivation deficient form of p53-D281  G (Box 2). The reasons 
for this are unknown. Perhaps, in order to induce repression of genes, mutant p53 
requires an interaction with another factor. The two additional mutations, which disrupt 
T AF interactions and c-terminal modifications, may be involved in this interaction. In 
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short, mutating these two residues may prevent or disrupt the interaction between mutant 
p53 and this second factor resulting in up-regulation of genes rather than repression. 
Finally, it is clear from the figure that although mutant p53 up-regulates a number of 
genes in H 1 299 cells, this is not the case when the mutant protein is expressed in 2 1  PT 
cells (Box 1 ). This is most likely due to the level of stringency used during the analysis. 
A less stringent analysis reveals a larger number of genes similarly regulated in both 
2 1 PT and H1 299 cells (data not shown). Nonetheless, it is evident that expression of 
mutant p53 in H1299 does not lead to a similar transcriptional regulation of genes in 
H1 299 and 2 l PT cells. Perhaps mutant p53 regulation of genes is partially dependent on 
the genetic background of the cells. 
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